

(51) International Patent Classification:
A61K 31/20 (2006.01)(21) International Application Number:
PCT/US2013/023201(22) International Filing Date:
25 January 2013 (25.01.2013)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
61/591,036 26 January 2012 (26.01.2012) US
13/478,990 23 May 2012 (23.05.2012) US(71) Applicant: **DIGNITY SCIENCES LIMITED** [IE/IE];
c/o Dignity Sciences Limited, 3rd Floor, Trintech Building,
South County Business Park, Leopardstown, Dublin 18
(IE).(71) Applicant (for US only): **CLIMAX, John** [IE/IE]; c/o 3rd
Floor, Trintech Building, South County Business Park,
Leopardstown, Dublin 18 (IE).

(72) Inventors; and

(71) Applicants (for US only): **ROWE, Jonathan** [US/IE]; c/o
Dignity Sciences Limited, 3rd Floor, Trintech Building,
South County Business Park, Leopardstown, Dublin 18
(IE). **COUGHLAN, David** [EC/IE]; c/o Dignity Sciences
Limited, 3rd Floor, Leopardstown, Dublin 18 (IE).
MANKU, Mehar [GB/IE]; c/o Dignity Sciences Limited,3rd Floor, Trintech Building, South County Business Park,
Leopardstown, Dublin 18 (IE).(74) Agents: **FOURNIER, David B.** et al.; K&L GATES LLP,
P.O. Box 1135, Chicago, Illinois 60690-1135 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ANTIMICROBIAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA AND/OR 15-HETRE AND METHODS OF
USE THEREOF(57) Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) in-
cluding, for example, DGLA, 15-OHEPA and/or 15-HETRE, used alone or in combination with one or more antibiotic agents for the
treatment of disease and/or disorders such as a skin infection or wound healing.

TITLE

**ANTIMICROBIAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA
AND/OR 15-HETRE AND METHODS OF USE THEREOF**

FIELD

[0001] The disclosure generally relates to compositions comprising fatty acids including, for example, DGLA, 15-OHEPA and/or 15-HETrE, alone or in combination with one or more antibiotic or anti-fungal agents for the treatment of disease and/or disorders such as a skin or gingival infection.

BACKGROUND

[0002] Scores of different microbial species colonize the skin and oral cavity as normal flora. However, when the skin's normal continuity or the oral microenvironment becomes disrupted, the resulting contusions, wounds, lesions, incisions, pockets, lacerations, and/or other disruptions can become infected by a wide variety of microbial species, some of which have become or are rapidly becoming resistant to existing therapies. Accordingly, there exists a need for compositions that are more effective in the treatment of skin and oral infections.

SUMMARY

[0003] The present disclosure provides compositions comprising one or more fatty acids agents including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used alone or in combination with antibiotic agents for the treatment of disease and/or disorders of the skin and gingiva.

[0004] The present disclosure also provides methods for treating or preventing skin and gingival infections in a subject in need thereof comprising administering to the subject an antimicrobial composition (*e.g.*, a composition having antimicrobial properties or a antimicrobial composition) comprising a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE or combinations thereof alone or in combination with one or more antibiotic agents. In some embodiments, the antimicrobial composition comprises about 0.1 wt.% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE.

[0005] In some embodiments, the antimicrobial composition comprises a sub-therapeutic amount of one or more of DGLA, 15-OHEPA, or 15-HETrE along with a therapeutic amount of one or more antibiotic agents. In some embodiments, the antimicrobial composition comprises a therapeutic amount of one or more of DGLA, 15-OHEPA, or 15-HETrE along with a sub-therapeutic amount of one or more antibiotic agents. In some embodiments, the antimicrobial composition comprises a sub-therapeutic amount of one or more of DGLA, 15-OHEPA, or 15-HETrE along with a sub-therapeutic amount of one or more antibiotic agents.

[0006] In some embodiments, the antimicrobial composition comprises one or more pharmaceutically acceptable excipients.

[0007] In some embodiments, the one or more antibiotic agents are selected from the group consisting of: neomycin sulfate, polymyxin B, bacitracin zinc, β -lactams (*e.g.*, ampicillin, amoxicillin, imipenem, meropenem), carbapenems, cephalosporins (*e.g.*, cephalexin, cephalothin, cefalozin, cefuroxime, cefotaxime, ceftazidime), fluoroquinolones, oxazolidinones, lincosamides, metronidazole, macrolide antibiotics (*e.g.*, clindamycin, erythromycin), quinolone antibiotics (*e.g.*, levofloxacin, ciprofloxacin), penicillins, glycopeptides (*e.g.*, vancomycin), aminoglycosides (*e.g.*, neomycin, gentamicin, tobramycin), trimethoprim/sulfamethoxazole (also known as co-trimoxazole or TMP/SMX), doxycycline, triclosan, metronidazole, monocycline and tetracycline.

[0008] In some embodiments, the one or more antibiotic agents are selected from the group consisting of: neomycin salts (*e.g.*, neomycin sulfate), polymyxin B, and/or bacitracin salts (*e.g.*, bacitracin zinc). In some embodiments, the one or more antibiotic agents are neomycin sulfate, polymyxin B and bacitracin zinc.

[0009] In some embodiments, the step of administering comprises topically applying the composition to an area of the skin or gingival afflicted with lesions. As used herein, the term "lesion" refers broadly to any disruption in the normal continuity and function of the skin or gingiva and includes, for example, contusions, wounds, burns, sores, ulcers, scrapes, incisions, lacerations, skin infection, gingivitis and periodontal disease. In some embodiments, the area of the skin afflicted with lesions is washed prior to application of the antimicrobial composition. In some embodiments, the lesions are inflammatory type and/or non-inflammatory type lesions.

[0010] In some embodiments, applying the composition results in about a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more reduction in the lesion.

[0011] In some embodiments, the lesion is associated with a microbe such as gram positive bacteria, gram negative bacteria or fungi.

[0012] In some embodiments, the lesion is associated with one or more of: *Staphylococcus spp.*, *Propionibacterium spp.*, *Streptococcus spp.*, *Corynebacterium spp.*, *Porphyromonas spp.*, *Micrococcus spp.*, *Pseudomonas aeruginosa*, *Pasteurella multocida*, *Capnocytophaga canimorsus*, *Bartonella spp.*, *Klebsiella rhinoscleromatis*, *Helicobacter spp.*, *Aspergillus niger*, *Aureobasidium pullulans*, *Chaetomium globosum*, *Gliocladium virens*, *Penicillium funiculosum*, *Candida albicans*, *Saccharomyces cerevisiae* and *Vibrio vulnificus*.

[0013] In some embodiments, the antimicrobial composition is administered to the subject once a day, twice a day, or three times a day.

[0014] In some embodiments, the antimicrobial composition is a cream, lotion, gel or emulsion.

[0015] In some embodiments, the subject previously exhibited lesions.

[0016] The present disclosure also provides methods of treating or preventing a microbial infection (e.g. a skin or gingival infection) in a subject in need thereof comprising administering to the subject an antimicrobial composition comprising a therapeutically effective amount of DGLA. In some embodiments, the antimicrobial composition comprises about 0.1% to about 20 wt.% of DGLA.

[0017] In some embodiments, the step of administering comprises topically applying the composition to an area of the skin or gingiva afflicted with lesions. In some embodiments, the area of the skin afflicted with lesions is first washed prior to application of the antimicrobial composition.

[0018] In some embodiments, the lesions are inflammatory type and/or non-inflammatory type lesions.

[0019] In some embodiments, the composition reduces about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the lesion.

[0020] In some embodiments, the lesion is associated with one or more of: *Staphylococcus* spp., *Propionibacterium* spp., *Streptococcus* spp., *Corynebacterium* spp., *Porphyromonas* spp., *Micrococcus* spp., *Pseudomonas aeruginosa*, *Pasteurella multocida*, *Capnocytophaga canimorsus*, *Bartonella* spp., *Klebsiella rhinoscleromatis*, *Helicobacter* spp., *Aspergillus niger*, *Aureobasidium pullulans*, *Chaetomium globosum*, *Gliocladium virens*, *Penicillium funiculosum*, *Candida albicans*, *Saccharomyces cerevisiae* and *Vibrio vulnificus*.

[0021] In some embodiments, the antimicrobial composition is administered to the subject once a day, twice a day, or three times a day.

[0022] In some embodiments, the antimicrobial composition is a cream, lotion, gel, rinse, paste or emulsion.

[0023] In some embodiments, the subject previously exhibited a lesion.

[0024] The present disclosure also provides compositions for use in treating a skin or oral infection (e.g. a microbial, bacterial or fungal infection) comprising a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE. In some embodiments, the composition comprises about 0.1% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE. In some embodiments, the therapeutically effective amount is an amount sufficient to kill or eradicate the microbe in one to a plurality of administrations.

[0025] The present disclosure also provides methods for treating or preventing microbial (e.g. bacterial or fungal) infection on the skin or gingiva comprising applying to the lesion one or more of DGLA, 15-OHEPA, or 15-HETrE. In some embodiments, the composition comprises about 0.1% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE.

[0026] The present disclosure also provides methods for improving the antimicrobial activity of an agent used in the treatment or prevention of skin or gingival infections comprising adding a composition comprising one or more of DGLA, 15-OHEPA, or 15-HETrE to the agent. In some embodiments, the agent used in the treatment or prevention of skin or gingival infections is an antibiotic or antifungal agent. In some embodiments, the composition comprises about 0.1% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE.

[0027] The present disclosure also provides methods of inhibiting one or more skin or gingival pathogens including, for example, its reproduction, growth or recolonization,

comprising contacting the one or more skin or oral pathogens with a composition comprising DGLA, 15-OHEPA, or 15-HETrE. In some embodiments, the composition comprises about 0.1% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE.

[0028] In some embodiments, the methods may further comprise administering to the subject a steroid. In some embodiments, the steroid is a corticosteroid such as hydrocortisone, prednicarbate, fluticasone and derivatives thereof, or mometasone and derivatives thereof.

[0029] In some embodiments, the subject is administered the therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE, the one or more antibiotic agents, and the steroid concomitantly.

[0030] In some embodiments, the antimicrobial composition comprises about 0.1 wt.% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE.

[0031] In some embodiments, the step of administering comprises topically applying the composition to an area afflicted with contusions, wounds, burns, sores, ulcers, scrapes, incisions, lacerations, skin infection, gingivitis or periodontal disease. .

[0032] In some embodiments, the area afflicted with contusions, wounds, burns, sores, ulcers, scrapes, incisions, lacerations, skin infection, gingivitis or periodontal disease. is first washed prior to application of the antimicrobial composition.

[0033] In some embodiments, the antimicrobial composition is administered to the subject once a day, twice a day, or three times a day.

[0034] In some embodiments, the antimicrobial compositions described herein are in the form of a cream, lotion, paste, gel, etc.

[0035] The present disclosure also provides methods for improving the efficacy of an agent used in the treatment of contusions, wounds, burns, sores, ulcers, scrapes, incisions, lacerations, skin infection, gingivitis or periodontal disease comprising adding a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE to the agent. In some embodiments, the agent is one or more antibiotic agents.

[0036] In some embodiments, about 0.1% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE is added to the agent.

[0037] The present disclosure also provides methods for reducing the efficacious dose of an agent used in the treatment of contusions, wounds, burns, sores, ulcers, scrapes, incisions, lacerations, skin infection, gingivitis or periodontal disease comprising adding a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE to the agent.

[0038] In some embodiments, about 0.1% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE is added to the agent.

[0039] These and other embodiments of the invention are described in further detail below.

BRIEF DESCRIPTION OF THE FIGURE

[0040] FIG. 1 depicts measurements obtained to determine the CZOI values for in vitro inhibition of bacterial growth according to one embodiment of the present disclosure.

DETAILED DESCRIPTION

[0041] The present disclosure provides compositions (*e.g.*, antimicrobial compositions) and formulations that comprise fatty acid agents including, for example, DGLA, 15-OHEPA and/or 15-HETrE alone; or with one or more antibiotic agents, for example, neomycin sulfate, polymyxin B, and/or bacitracin zinc. Such agents have been found to reduce including, inhibit, the growth of bacteria associated with skin and gingival infections such as *Staphylococcus* spp. (including, for example, *S. aureus*, *S. lugdunensis*, *S. schleiferi* and other coagulase-negative *Staphylococcus* spp.), *Streptococcus* spp. (including, for example, β -haemolytic *Streptococci*, Viridans group *Streptococci*, non-haemolytic *Streptococci*, and *Streptococcus milleri* group), *Corynebacterium* spp., *Bacillus* spp. (including, for example, *B. anthracis* and *B. cereus*), *Acinetobacter* spp., *Moraxella* spp., *Peptostreptococcus* spp., *Propionibacterium* spp., (including, for example, *P. Acnes*), *Candida* spp., *Pseudomonas* spp. and other non-fermentative bacilli (including, for example, *P. aeruginosa*), Dermatophytes, Enterobacteriaceae, *Pasturella multocida*, *Mycobacterium* spp., *Haemophilus* spp., *Nocardia* spp., *Erysipelothrix rhusiopathiae*, *Vibrio* spp., *Enterococcus* spp., *Eikenella corrodens*, anaerobes, *Corynebacterium* spp., *Actinomyces* spp., and fungal pathogens. Furthermore, the inventors have found that, in many cases, the use of these fatty acid agents in combination with existing antibacterial agents (*e.g.*, nicotinamide, benzoyl peroxide, adapalene, metronidazole, neomycin sulfate, polymyxin B, bacitracin zinc, β -lactams (*e.g.*, ampicillin, amoxicillin, imipenem, meropenem), carbapenems, cephalosporins (*e.g.*, cephalexin,

cephalothin, cefalozin, cefuroxime, cefotaxime, ceftazidime), fluoroquinolones, oxazolidinones, lincosamides, macrolide antibiotics (*e.g.*, clindamycin, erythromycin), quinolone antibiotics (*e.g.*, levofloxacin, ciprofloxacin), penicillins, triclosan, monocycline, glycopeptides (*e.g.*, vancomycin), aminoglycosides (*e.g.*, neomycin, gentamicin, tobramycin), trimethoprim/sulfamethoxazole (also known as co-trimoxazole or TMP/SMX), doxycycline and tetracycline) provides additional reduction in the growth of bacteria compared to each agent used singly. Given their capacity to reduce, inhibit and/or prevent, the growth of bacteria, the compositions and formulations disclosed herein may be used in the treatment of disease and/or disorders associated with the growth of bacteria.

[0042] The present disclosure provides compositions comprising fatty acids including, for example, DGLA, 15-OHEPA and/or 15-HETrE in free acid or derivative form, used in combination with antibacterial agents including, for example, nicotinamide, benzoyl peroxide, adapalene, metronidazole, neomycin sulfate, polymyxin B, and bacitracin zinc and triclosan. In some embodiments, the compositions comprise about 0.1 wt.% to about 20 wt.% of DGLA, 15-OHEPA, or 15-HETrE or derivative thereof. Contemplated combinations include, without limitation, DGLA and neomycin sulfate; 15-OHEPA and neomycin sulfate; 15 HETrE and neomycin sulfate; DGLA and polymyxin B; 15-OHEPA and polymyxin B; 15 HETrE and polymyxin B; DGLA and bacitracin zinc; 15-OHEPA and bacitracin zinc; and 15-HETrE and bacitracin zinc; DGLA, neomycin sulfate, polymyxin B and bacitracin zinc; 15-OHEPA neomycin sulfate, polymyxin B and bacitracin zinc; and 15 HETrE neomycin sulfate, polymyxin B and bacitracin zinc. In some embodiments, a composition comprising DGLA, 15-OHEPA and/or 15-HETrE includes a therapeutically effective amount of neomycin sulfate. In some embodiments, a composition comprising DGLA, 15-OHEPA and/or 15-HETrE includes a therapeutically effective amount of polymyxin B. In some embodiments, a composition comprising DGLA, 15-OHEPA and/or 15-HETrE includes a therapeutically effective amount of bacitracin zinc.

[0043] While the present disclosure is capable of being embodied in various forms, the description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the disclosure, and is not intended to limit the disclosure to the specific embodiments illustrated. Headings are provided for convenience only and are not to be construed to limit the disclosure in any manner.

Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.

[0044] The use of numerical values in the various quantitative values specified in this application, unless expressly indicated otherwise, are stated as approximations as though the minimum and maximum values within the stated ranges were both preceded by the word “about.” Also, the disclosure of ranges is intended as a continuous range including every value between the minimum and maximum values recited as well as any ranges that can be formed by such values. Also disclosed herein are any and all ratios (and ranges of any such ratios) that can be formed by dividing a disclosed numeric value into any other disclosed numeric value. Accordingly, the skilled person will appreciate that many such ratios, ranges, and ranges of ratios can be unambiguously derived from the numerical values presented herein and in all instances such ratios, ranges, and ranges of ratios represent various embodiments of the present disclosure.

[0045] Dihomo-gamma-linolenic acid, also known as *cis*-8,11,14-eicosatrienoic acid or C 20:3 ω 6 (“DGLA”), is the elongation product of gamma-linolenic acid, also referred to as gammaoleic acid or C 18:3 ω 6 (“GLA”). GLA is a component of natural oils from a variety of plants such as Echium, blackcurrant, borage, evening primrose, hackelia, trichodesma, and buglossoides, to name a few. As used herein, the term “DGLA” refers to DGLA free acid (*e.g.*, *cis*-8,11,14-eicosatrienoic acid) and/or a pharmaceutically acceptable ester, derivative, conjugate or salt thereof, or mixtures of any of the foregoing. In some embodiments, DGLA is in the form of a C₁₋₄ alkyl ester such as methyl ester or ethyl ester form.

[0046] 15-Hydroxy-eicosa-5,8,11,13,17-pentaenoic acid (“15-OHEPA”) is a derivative of EPA. As used herein, the term “15-OHEPA” refers to 15-OHEPA in its free acid form (*e.g.*, 15-hydroxy-eicosa-5,8,11,13,17-pentaenoic acid) and/or a pharmaceutically acceptable ester, derivative, conjugate or salt thereof, or mixtures of any of the foregoing. In some embodiments, the 15-OHEPA is in the form of a C₁₋₄ alkyl ester such as methyl ester or ethyl ester form.

[0047] 15-Hydroxy-eicosa-8(Z),11(Z),13(E)-trienoic acid (“15-HETrE”) is a derivative of DGLA. As used herein, the term “15-HETrE” refers to 15-HETrE in its free acid form (*e.g.*, 15-hydroxy-eicosa-8(Z),11(Z),13(E)-trienoic acid) and/or a pharmaceutically acceptable ester, derivative, conjugate or salt thereof, or mixtures of any of the foregoing.

[0048] As used herein, the terms “DGLA derivative” and “derivative of DGLA” refer to compounds formed from the chemical conversion of DGLA including, without limitation, 15-HETrE, and esters, derivatives, conjugates or salts thereof, or mixtures of any of the foregoing. One of skill in the art will readily recognize from the chemical structure and other properties whether a given compound is a DGLA derivative.

[0049] In one embodiment, DGLA, 15-OHEPA, and/or 15-HETrE is deodorized prior to use in a method or composition as disclosed herein. In one embodiment, crude DGLA, 15-OHEPA, and/or 15-HETrE is mixed with silica and charcoal. In one embodiment, the silica and charcoal are in a ratio of about 1:1 to about 50:1, for example about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 12:1, about 14:1, about 15:1, about 16:1, about 18:1, about 20:1, about 25:1, about 30:1, about 35:1, about 40:1, about 45:1, or about 50:1. In one embodiment, the ratio of DGLA (or 15-OHEPA or 15-HETrE) to silica/charcoal is about 1:1 to about 50:1, for example about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 12:1, about 14:1, about 15:1, about 16:1, about 18:1, about 20:1, about 25:1, about 30:1, about 35:1, about 40:1, about 45:1, or about 50:1. In one embodiment, crude DGLA, 15-OHEPA, and/or 15-HETrE has been deodorized by filtering over a CELITE filter. In another embodiment, lecithin is used in the deodorizing of the fatty acids.

[0050] In various embodiments, the invention provides antimicrobial compositions, for example topically deliverable compositions, comprising one or more of DGLA, 15-OHEPA, 15-HETrE or mixtures thereof.

[0051] In one embodiment, the present disclosure provides antimicrobial compositions comprising, for example, an amount (*e.g.*, a therapeutically effective amount) of DGLA, 15-OHEPA, 15-HETrE, or a combination thereof. In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 20 wt.% of the DGLA, 15-OHEPA, 15-HETrE, or a combination thereof, for example about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%,

about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, about 5 wt.%, about 5.1 wt.%, about 5.2 wt.%, about 5.3 wt.%, about 5.4 wt.%, about 5.5 wt.%, about 5.6 wt.%, about 5.7 wt.%, about 5.8 wt.%, about 5.9 wt.%, about 6 wt.%, about 6.1 wt.%, about 6.2 wt.%, about 6.3 wt.%, about 6.4 wt.%, about 6.5 wt.%, about 6.6 wt.%, about 6.7 wt.%, about 6.8 wt.%, about 6.9 wt.%, about 7 wt.%, about 7.1 wt.%, about 7.2 wt.%, about 7.3 wt.%, about 7.4 wt.%, about 7.5 wt.%, about 7.6 wt.%, about 7.7 wt.%, about 7.8 wt.%, about 7.9 wt.%, about 8 wt.%, about 8.1 wt.%, about 8.2 wt.%, about 8.3 wt.%, about 8.4 wt.%, about 8.5 wt.%, about 8.6 wt.%, about 8.7 wt.%, about 8.8 wt.%, about 8.9 wt.%, about 9 wt.%, about 9.1 wt.%, about 9.2 wt.%, about 9.3 wt.%, about 9.4 wt.%, about 9.5 wt.%, about 9.6 wt.%, about 9.7 wt.%, about 9.8 wt.%, about 9.9 wt.%, about 10 wt.%, about 10.1 wt.%, about 10.2 wt.%, about 10.3 wt.%, about 10.4 wt.%, about 10.5 wt.%, about 10.6 wt.%, about 10.7 wt.%, about 10.8 wt.%, about 10.9 wt.%, about 11 wt.%, about 11.1 wt.%, about 11.2 wt.%, about 11.3 wt.%, about 11.4 wt.%, about 11.5 wt.%, about 11.6 wt.%, about 11.7 wt.%, about 11.8 wt.%, about 11.9 wt.%, about 12 wt.%, about 12.1 wt.%, about 12.2 wt.%, about 12.3 wt.%, about 12.4 wt.%, about 12.5 wt.%, about 12.6 wt.%, about 12.7 wt.%, about 12.8 wt.%, about 12.9 wt.%, about 13 wt.%, about 13.1 wt.%, about 13.2 wt.%, about 13.3 wt.%, about 13.4 wt.%, about 13.5 wt.%, about 13.6 wt.%, about 13.7 wt.%, about 13.8 wt.%, about 13.9 wt.%, about 14 wt.%, about 14.1 wt.%, about 14.2 wt.%, about 14.3 wt.%, about 14.4 wt.%, about 14.5 wt.%, about 14.6 wt.%, about 14.7 wt.%, about 14.8 wt.%, about 14.9 wt.%, about 15 wt.%, about 15.1 wt.%, about 15.2 wt.%, about 15.3 wt.%, about 15.4 wt.%, about 15.5 wt.%, about 15.6 wt.%, about 15.7 wt.%, about 15.8 wt.%, about 15.9 wt.%, about 16 wt.%, about 16.1 wt.%, about 16.2 wt.%, about 16.3 wt.%, about 16.4 wt.%, about 16.5 wt.%, about 16.6 wt.%, about 16.7 wt.%, about 16.8 wt.%, about 16.9 wt.%, about 17 wt.%, about 17.1 wt.%, about 17.2 wt.%, about 17.3 wt.%, about 17.4 wt.%, about 17.5 wt.%, about 17.6 wt.%, about 17.7 wt.%, about 17.8 wt.%, about 17.9 wt.%, about 18 wt.%, about 18.1 wt.%, about 18.2 wt.%, about 18.3 wt.%, about 18.4 wt.%, about 18.5 wt.%, about 18.6 wt.%, about 18.7 wt.%, about 18.8 wt.%, about 18.9 wt.%, about 19 wt.%, about 19.1 wt.%, about 19.2 wt.%, about 19.3 wt.%, about 19.4 wt.%, about 19.5 wt.%, about 19.6 wt.%, about

19.7 wt.%, about 19.8 wt.%, about 19.9 wt.%, or about 20 wt% of the DGLA, 15-OHEPA, 15-HETrE, or a combination thereof.

[0052] In one embodiment, the antimicrobial composition further comprises an additional active agent. In one embodiment, the antimicrobial composition comprises an amount of the additional active agent that is less than the generally recognized therapeutically effective amount for that agent. In one embodiment, the antimicrobial composition comprises an amount of the additional active agent that is equal to or greater than the generally recognized therapeutically effective amount for that agent. In one embodiment, the additional active agent has not previously been recognized as effective in the treatment or prevention of skin or gingival infections. In another embodiment, the additional active agent is approved for use in the treatment or prevention of skin or gingival infections. In one embodiment, the additional active agent is an antibiotic agent.

[0053] In one embodiment, the additional active agent is neomycin sulfate (also referred to as (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol, sulfuric acid). In one embodiment, the antimicrobial composition comprises an amount of neomycin sulfate that is less than the generally recognized therapeutically effective amount. In one embodiment, the antimicrobial composition comprises an amount of neomycin sulfate that is equal to or greater than the generally recognized therapeutically effective amount. In one embodiment, the antimicrobial composition comprises about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition, for example about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75 mg, or about 10 mg of neomycin sulfate per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises less than about 3.5 mg of neomycin sulfate per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises about 3.5 mg of neomycin sulfate per gram of antimicrobial composition. In one

embodiment, the antimicrobial composition comprises more than about 3.5 mg of neomycin sulfate per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises no neomycin sulfate.

[0054] In one embodiment, the additional active agent is polymyxin B, a mixture of polymyxin B1 and polymyxin B2 (also referred to as Aerosporin, PMB, and N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-hepta-oxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide). In one embodiment, the antimicrobial composition comprises an amount of polymyxin B that is less than the generally recognized therapeutically effective amount. In one embodiment, the antimicrobial composition comprises an amount of the polymyxin B that is equal to or greater than the generally recognized therapeutically effective amount. In one embodiment, the antimicrobial composition comprises about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition (about 119 µg to about 2.38 mg of polymyxin B per gram of antimicrobial composition), for example about 1,000 units, about 1,500 units, about 2,000 units, about 2,500 units, about 3,000 units, about 3,500 units, about 4,000 units, about 4,500 units, about 5,000 units, about 5,500 units, about 6,000 units, about 6,500 units, about 7,000 units, about 7,500 units, about 8,000 units, about 8,500 units, about 9,000 units, about 9,500 units, about 10,000 units, about 10,500 units, about 11,000 units, about 11,500 units, about 12,000 units, about 12,500 units, about 13,000 units, about 13,500 units, about 14,000 units, about 14,500 units, about 15,000 units, about 15,500 units, about 16,000 units, about 16,500 units, about 17,000 units, about 17,500 units, about 18,000 units, about 18,500 units, about 19,000 units, about 19,500 units, or about 20,000 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises less than about 5,000 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises less than about 10,000 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises more than about 5,000 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises more than about 10,000 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises about 5,000 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises about 5,000 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises

about 6,500 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises about 10,000 units of polymyxin B per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises no polymyxin B.

[0055] In one embodiment, the additional active agent is bacitracin zinc. In one embodiment, the antimicrobial composition comprises an amount of bacitracin zinc that is less than the generally recognized therapeutically effective amount. In one embodiment, the antimicrobial composition comprises an amount of the bacitracin zinc that is equal to or greater than the generally recognized therapeutically effective amount. In one embodiment, the antimicrobial composition comprises about 100 units to about 800 units of bacitracin zinc (about 2.5 mg to about 20 mg of bacitracin zinc per gram of antimicrobial composition), for example about 100 units, about 125 units, about 150 units, about 175 units, about 200 units, about 225 units, about 250 units, about 275 units, about 300 units, about 325 units, about 350 units, about 375 units, about 400 units, about 425 units, about 450 units, about 475 units, about 500 units, about 525 units, about 550 units, about 575 units, about 600 units, about 625 units, about 650 units, about 675 units, about 700 units, about 725 units, about 750 units, about 775 units, or about 800 units of bacitracin zinc per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises less than about 400 units of bacitracin zinc per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises about 400 units of bacitracin zinc per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises more than about 400 units of bacitracin zinc per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises less than about 500 units of bacitracin zinc per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises about 500 units of bacitracin zinc per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises more than about 500 units of bacitracin zinc per gram of antimicrobial composition. In one embodiment, the antimicrobial composition comprises no bacitracin zinc.

[0056] In one embodiment, the additional active agents are neomycin sulfate, polymyxin B and bacitracin zinc. In one embodiment, the antimicrobial composition comprises an amount of one or more of neomycin sulfate, an amount of polymyxin B and/or an amount of bacitracin zinc that is less than the generally recognized therapeutically effective amount. In

one embodiment, the antimicrobial composition comprises an amount of neomycin sulfate, an amount of polymyxin B and an amount of bacitracin zinc that are each less than the generally recognized therapeutically effective amount. In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 5,000 units of polymyxin B, and about 400 units of bacitracin zinc. In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 10,000 units of polymyxin B, and about 500 units of bacitracin zinc. In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 10,000 units of polymyxin B, and no bacitracin zinc.

[0057] In one embodiment, the additional active ingredient is triclosan. In one embodiment the antimicrobial composition comprises 0.1-1% triclosan, by weight or by volume. In another embodiment the antimicrobial composition comprises an amount of triclosan that is less than the generally recognized therapeutically effective amount.

[0058] In one embodiment, the antimicrobial composition further comprises an analgesic agent. In one embodiment, the analgesic agent is a topical or systemic analgesic. In one embodiment, the analgesic agent is a topical or systemic analgesic selected from the group consisting of: ibuprofen, diclofenac, capsaicin, lidocaine, and pramoxine HCl.

[0059] In one embodiment, the analgesic agent is pramoxine HCl (also referred to as pramocaine HCl, INN, or BAN). In one embodiment, the antimicrobial composition comprises an amount of pramoxine HCl that is less than the generally recognized therapeutically effective amount. In one embodiment, the antimicrobial composition comprises an amount of pramoxine HCl that is equal to or greater than the generally recognized therapeutically effective amount. In one embodiment, the antimicrobial composition comprises about 1 mg to about 20 mg of pramoxine HCl per gram of antimicrobial composition, for example about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 11.5 mg, about 12 mg, about 12.5 mg, about 13 mg, about 13.5 mg, about 14 mg, about 14.5 mg, about 15 mg, about 15.5 mg, about 16 mg, about 16.5 mg, about 17 mg, about 17.5 mg, about 18 mg, about 18.5 mg, about 19 mg, about 19.5 mg, or about 20 mg of pramoxine HCl per gram of antimicrobial composition.

[0060] In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 10,000 units of polymyxin B, about 500 units of bacitracin zinc, and about 1 mg to about 20 mg of pramoxine HCl. In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 10,000 units of polymyxin B, about 500 units of bacitracin zinc, and about 1 mg to less than about 10 mg of pramoxine HCl. In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 10,000 units of polymyxin B, about 500 units of bacitracin zinc, and about 10 mg of pramoxine HCl. In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 10,000 units of polymyxin B, no bacitracin zinc, and about 1 mg to about 20 mg of pramoxine HCl. In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 10,000 units of polymyxin B, no bacitracin zinc, and about 1 mg to less than about 10 mg of pramoxine HCl. In one embodiment, one gram of antimicrobial composition comprises about 3.5 mg of neomycin sulfate, about 10,000 units of polymyxin B, no bacitracin zinc, and about 10 mg of pramoxine HCl.

[0061] Any pharmaceutically acceptable excipient known to those of skill in the art may be used in antimicrobial compositions according to the present disclosure. Any excipient selected for use in the therapeutic and cosmetic compositions should be pharmaceutically and/or cosmetically acceptable and appropriate for the form in which the therapeutic composition will be used, *e.g.*, cream, gel, milk, oil, lotion, paste and the like. Preferably, the excipient has an affinity for the skin or gingiva, is well tolerated, and stable when used in an amount adequate to provide the desired consistency and ease of application. By way of example only, an antimicrobial composition according to the present disclosure may comprise one or more of: surfactants, preservatives, flavouring agents, co-solvents, viscosity aids, suspension aids, and lipophilic phases. In one embodiment, the antimicrobial composition comprises excipients suitable for an orally deliverable composition or for a tooth paste. In another embodiment, the composition comprises one or more of: calcium phosphate, cocoa butter, cottonseed oil, fluoride, hydroxyapatite nanocrystals, olive oil, sodium pyruvate, sugar alcohols (*e.g.* glycerol, sorbitol, xylitol), surfactants (*e.g.* sodium lauryl sulfate or other detergents) vitamin E, white petrolatum, emulsifying wax, methylparaben, mineral oil, poloxamer 188, propylene glycol, zinc chloride, and purified water. In one embodiment, the antimicrobial composition comprises cocoa butter, cottonseed oil, olive oil, sodium pyruvate, sodium triphosphate, vitamin E, and white petrolatum. In

one embodiment, the antimicrobial composition comprises white petrolatum. In one embodiment, the antimicrobial composition comprises emulsifying wax, methylparaben, mineral oil, poloxamer 188, propylene glycol, purified water, and white petrolatum.

[0062] In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 5 wt.% of a surfactant such as an ethoxylated natural fatty alcohol (*e.g.*, Steareth-2), for example, about 0.5 wt.%, about 0.55 wt.%, about 0.6 wt.%, about 0.65 wt.%, about 0.7 wt.%, about 0.75 wt.%, about 0.8 wt.%, about 0.85 wt.%, about 0.9 wt.%, about 0.95 wt.%, about 1 wt.%, about 1.05 wt.%, about 1.1 wt.%, about 1.15 wt.%, about 1.2 wt.%, about 1.25 wt.%, about 1.3 wt.%, about 1.35 wt.%, about 1.4 wt.%, about 1.45 wt.%, about 1.5 wt.%, about 1.55 wt.%, about 1.6 wt.%, about 1.65 wt.%, about 1.7 wt.%, about 1.75 wt.%, about 1.8 wt.%, about 1.85 wt.%, about 1.9 wt.%, about 1.95 wt.%, about 2 wt.%, about 2.05 wt.%, about 2.1 wt.%, about 2.15 wt.%, about 2.2 wt.%, about 2.25 wt.%, about 2.3 wt.%, about 2.35 wt.%, about 2.4 wt.%, about 2.45 wt.%, about 2.5 wt.%, about 2.55 wt.%, about 2.6 wt.%, about 2.65 wt.%, about 2.7 wt.%, about 2.75 wt.%, about 2.8 wt.%, about 2.85 wt.%, about 2.9 wt.%, about 2.95 wt.%, about 3 wt.%, about 3.05 wt.%, about 3.1 wt.%, about 3.15 wt.%, about 3.2 wt.%, about 3.25 wt.%, about 3.3 wt.%, about 3.35 wt.%, about 3.4 wt.%, about 3.45 wt.%, about 3.5 wt.%, about 3.55 wt.%, about 3.6 wt.%, about 3.65 wt.%, about 3.7 wt.%, about 3.75 wt.%, about 3.8 wt.%, about 3.85 wt.%, about 3.9 wt.%, about 3.95 wt.%, about 4 wt.%, about 4.05 wt.%, about 4.1 wt.%, about 4.15 wt.%, about 4.2 wt.%, about 4.25 wt.%, about 4.3 wt.%, about 4.35 wt.%, about 4.4 wt.%, about 4.45 wt.%, about 4.5 wt.%, about 4.55 wt.%, about 4.6 wt.%, about 4.65 wt.%, about 4.7 wt.%, about 4.75 wt.%, about 4.8 wt.%, about 4.85 wt.%, about 4.9 wt.%, about 4.95 wt.%, about 5 wt.% of the surfactant. In one embodiment the surfactant is Steareth-2 (*e.g.*, BRIJ S2, Croda International plc).

[0063] In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 5 wt.% of an emulsifier such as a polyoxyethylene fatty ether (*e.g.*, Steareth-21), for example, about 0.5 wt.%, about 0.55 wt.%, about 0.6 wt.%, about 0.65 wt.%, about 0.7 wt.%, about 0.75 wt.%, about 0.8 wt.%, about 0.85 wt.%, about 0.9 wt.%, about 0.95 wt.%, about 1 wt.%, about 1.05 wt.%, about 1.1 wt.%, about 1.15 wt.%, about 1.2 wt.%, about 1.25 wt.%, about 1.3 wt.%, about 1.35 wt.%, about 1.4 wt.%, about 1.45 wt.%, about 1.5 wt.%, about 1.55 wt.%, about 1.6 wt.%, about 1.65 wt.%, about 1.7 wt.%, about 1.75 wt.%, about 1.8 wt.%, about 1.85 wt.%, about 1.9 wt.%, about 1.95 wt.%, about 2 wt.%, about 2.05 wt.%,

about 2.1 wt.%, about 2.15 wt.%, about 2.2 wt.%, about 2.25 wt.%, about 2.3 wt.%, about 2.35 wt.%, about 2.4 wt.%, about 2.45 wt.%, about 2.5 wt.%, about 2.55 wt.%, about 2.6 wt.%, about 2.65 wt.%, about 2.7 wt.%, about 2.75 wt.%, about 2.8 wt.%, about 2.85 wt.%, about 2.9 wt.%, about 2.95 wt.%, about 3 wt.%, about 3.05 wt.%, about 3.1 wt.%, about 3.15 wt.%, about 3.2 wt.%, about 3.25 wt.%, about 3.3 wt.%, about 3.35 wt.%, about 3.4 wt.%, about 3.45 wt.%, about 3.5 wt.%, about 3.55 wt.%, about 3.6 wt.%, about 3.65 wt.%, about 3.7 wt.%, about 3.75 wt.%, about 3.8 wt.%, about 3.85 wt.%, about 3.9 wt.%, about 3.95 wt.%, about 4 wt.%, about 4.05 wt.%, about 4.1 wt.%, about 4.15 wt.%, about 4.2 wt.%, about 4.25 wt.%, about 4.3 wt.%, about 4.35 wt.%, about 4.4 wt.%, about 4.45 wt.%, about 4.5 wt.%, about 4.55 wt.%, about 4.6 wt.%, about 4.65 wt.%, about 4.7 wt.%, about 4.75 wt.%, about 4.8 wt.%, about 4.85 wt.%, about 4.9 wt.%, about 4.95 wt.%, about 5 wt.% of the emulsifier. In one embodiment the emulsifier is Steareth-21 (*e.g.*, BRIJ S721, Croda International plc).

[0064] In one embodiment, the antimicrobial composition comprises a stabilizer such as a cetyl alcohol or a saturated cetyl alcohol (*e.g.*, cetyl alcohol). In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 5 wt.% of a stabilizer, for example about 0.1 wt.%, about 0.11 wt.%, about 0.12 wt.%, about 0.13 wt.%, about 0.14 wt.%, about 0.15 wt.%, about 0.16 wt.%, about 0.17 wt.%, about 0.18 wt.%, about 0.19 wt.%, about 0.2 wt.%, about 0.21 wt.%, about 0.22 wt.%, about 0.23 wt.%, about 0.24 wt.%, about 0.25 wt.%, about 0.26 wt.%, about 0.27 wt.%, about 0.28 wt.%, about 0.29 wt.%, about 0.3 wt.%, about 0.31 wt.%, about 0.32 wt.%, about 0.33 wt.%, about 0.34 wt.%, about 0.35 wt.%, about 0.36 wt.%, about 0.37 wt.%, about 0.38 wt.%, about 0.39 wt.%, about 0.4 wt.%, about 0.41 wt.%, about 0.42 wt.%, about 0.43 wt.%, about 0.44 wt.%, about 0.45 wt.%, about 0.46 wt.%, about 0.47 wt.%, about 0.48 wt.%, about 0.49 wt.%, about 0.5 wt.%, about 0.51 wt.%, about 0.52 wt.%, about 0.53 wt.%, about 0.54 wt.%, about 0.55 wt.%, about 0.56 wt.%, about 0.57 wt.%, about 0.58 wt.%, about 0.59 wt.%, about 0.6 wt.%, about 0.61 wt.%, about 0.62 wt.%, about 0.63 wt.%, about 0.64 wt.%, about 0.65 wt.%, about 0.66 wt.%, about 0.67 wt.%, about 0.68 wt.%, about 0.69 wt.%, about 0.7 wt.%, about 0.71 wt.%, about 0.72 wt.%, about 0.73 wt.%, about 0.74 wt.%, about 0.75 wt.%, about 0.76 wt.%, about 0.77 wt.%, about 0.78 wt.%, about 0.79 wt.%, about 0.8 wt.%, about 0.81 wt.%, about 0.82 wt.%, about 0.83 wt.%, about 0.84 wt.%, about 0.85 wt.%, about 0.86 wt.%, about 0.87 wt.%, about 0.88 wt.%, about 0.89 wt.%, about 0.9 wt.%, about 0.91 wt.%, about 0.92 wt.%, about 0.93 wt.%, about 0.94 wt.%, about 0.95 wt.%, about 0.96 wt.%, about 0.97 wt.%, about 0.98 wt.%, about 0.99 wt.%,

about 1 wt.%, about 1.01 wt.%, about 1.02 wt.%, about 1.03 wt.%, about 1.04 wt.%, about 1.05 wt.%, about 1.06 wt.%, about 1.07 wt.%, about 1.08 wt.%, about 1.09 wt.%, about 1.1 wt.%, about 1.11 wt.%, about 1.12 wt.%, about 1.13 wt.%, about 1.14 wt.%, about 1.15 wt.%, about 1.16 wt.%, about 1.17 wt.%, about 1.18 wt.%, about 1.19 wt.%, about 1.2 wt.%, about 1.21 wt.%, about 1.22 wt.%, about 1.23 wt.%, about 1.24 wt.%, about 1.25 wt.%, about 1.26 wt.%, about 1.27 wt.%, about 1.28 wt.%, about 1.29 wt.%, about 1.3 wt.%, about 1.31 wt.%, about 1.32 wt.%, about 1.33 wt.%, about 1.34 wt.%, about 1.35 wt.%, about 1.36 wt.%, about 1.37 wt.%, about 1.38 wt.%, about 1.39 wt.%, about 1.4 wt.%, about 1.41 wt.%, about 1.42 wt.%, about 1.43 wt.%, about 1.44 wt.%, about 1.45 wt.%, about 1.46 wt.%, about 1.47 wt.%, about 1.48 wt.%, about 1.49 wt.%, about 1.5 wt.%, about 1.51 wt.%, about 1.52 wt.%, about 1.53 wt.%, about 1.54 wt.%, about 1.55 wt.%, about 1.56 wt.%, about 1.57 wt.%, about 1.58 wt.%, about 1.59 wt.%, about 1.6 wt.%, about 1.61 wt.%, about 1.62 wt.%, about 1.63 wt.%, about 1.64 wt.%, about 1.65 wt.%, about 1.66 wt.%, about 1.67 wt.%, about 1.68 wt.%, about 1.69 wt.%, about 1.7 wt.%, about 1.71 wt.%, about 1.72 wt.%, about 1.73 wt.%, about 1.74 wt.%, about 1.75 wt.%, about 1.76 wt.%, about 1.77 wt.%, about 1.78 wt.%, about 1.79 wt.%, about 1.8 wt.%, about 1.81 wt.%, about 1.82 wt.%, about 1.83 wt.%, about 1.84 wt.%, about 1.85 wt.%, about 1.86 wt.%, about 1.87 wt.%, about 1.88 wt.%, about 1.89 wt.%, about 1.9 wt.%, about 1.91 wt.%, about 1.92 wt.%, about 1.93 wt.%, about 1.94 wt.%, about 1.95 wt.%, about 1.96 wt.%, about 1.97 wt.%, about 1.98 wt.%, about 1.99 wt.%, about 2 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, or about 5 wt% of the stabilizer. In one embodiment, the stabilizer is cetyl alcohol (*e.g.*, Crodacol C95 EP, Croda International plc).

[0065] In one embodiment, the antimicrobial composition comprises one or more antioxidants such as ascorbic acid, palmitic acid, ascorbyl palmitate, α -tocopherol, idebenone, ubiquinone, ferulic acid, coenzyme Q10, lycopene, green tea, catechins, epigallocatechin 3-gallate (EGCG), green tea polyphenols (GTP), silymarin, coffeeberry, resveratrol, grape seed, pomegranate extracts, genisten, pycnogenol, niacinamide, and the like. In one embodiment, the antimicrobial composition comprises about 0.01 wt.% to about 2 wt.% of an antioxidant, for example about 0.01 wt.%, about 0.02 wt.%, about 0.03 wt.%, about 0.04 wt.%, about

0.05 wt.%, about 0.06 wt.%, about 0.07 wt.%, about 0.08 wt.%, about 0.09 wt.%, about 0.1 wt.%, about 0.11 wt.%, about 0.12 wt.%, about 0.13 wt.%, about 0.14 wt.%, about 0.15 wt.%, about 0.16 wt.%, about 0.17 wt.%, about 0.18 wt.%, about 0.19 wt.%, about 0.2 wt.%, about 0.21 wt.%, about 0.22 wt.%, about 0.23 wt.%, about 0.24 wt.%, about 0.25 wt.%, about 0.26 wt.%, about 0.27 wt.%, about 0.28 wt.%, about 0.29 wt.%, about 0.3 wt.%, about 0.31 wt.%, about 0.32 wt.%, about 0.33 wt.%, about 0.34 wt.%, about 0.35 wt.%, about 0.36 wt.%, about 0.37 wt.%, about 0.38 wt.%, about 0.39 wt.%, about 0.4 wt.%, about 0.41 wt.%, about 0.42 wt.%, about 0.43 wt.%, about 0.44 wt.%, about 0.45 wt.%, about 0.46 wt.%, about 0.47 wt.%, about 0.48 wt.%, about 0.49 wt.%, about 0.5 wt.%, about 0.51 wt.%, about 0.52 wt.%, about 0.53 wt.%, about 0.54 wt.%, about 0.55 wt.%, about 0.56 wt.%, about 0.57 wt.%, about 0.58 wt.%, about 0.59 wt.%, about 0.6 wt.%, about 0.61 wt.%, about 0.62 wt.%, about 0.63 wt.%, about 0.64 wt.%, about 0.65 wt.%, about 0.66 wt.%, about 0.67 wt.%, about 0.68 wt.%, about 0.69 wt.%, about 0.7 wt.%, about 0.71 wt.%, about 0.72 wt.%, about 0.73 wt.%, about 0.74 wt.%, about 0.75 wt.%, about 0.76 wt.%, about 0.77 wt.%, about 0.78 wt.%, about 0.79 wt.%, about 0.8 wt.%, about 0.81 wt.%, about 0.82 wt.%, about 0.83 wt.%, about 0.84 wt.%, about 0.85 wt.%, about 0.86 wt.%, about 0.87 wt.%, about 0.88 wt.%, about 0.89 wt.%, about 0.9 wt.%, about 0.91 wt.%, about 0.92 wt.%, about 0.93 wt.%, about 0.94 wt.%, about 0.95 wt.%, about 0.96 wt.%, about 0.97 wt.%, about 0.98 wt.%, about 0.99 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, or about 2 wt.% of the one or more antioxidant.

[0066] In one embodiment the antioxidant is ascorbyl palmitate. In one embodiment the antioxidant is α -tocopherol. In one embodiment the antioxidant is ascorbic acid. In one embodiment the antioxidant is idebenone. In one embodiment, the antioxidant is ubiquinone. In one embodiment, the antioxidant is ferulic acid. In one embodiment, the antioxidant is coenzyme Q10. In one embodiment, the antioxidant is lycopene. In one embodiment, the antioxidant is green tea. In one embodiment, the antioxidant is catechins. In one embodiment, the antioxidant is epigallocatechin 3-gallate (EGCG). In one embodiment, the antioxidant is green tea polyphenols (GTP). In one embodiment, the antioxidant is silymarin. In one embodiment, the antioxidant is coffeeberry. In one embodiment, the antioxidant is resveratrol. In one embodiment, the antioxidant is grape seed. In one embodiment, the antioxidant is pomegranate extracts. In one embodiment, the antioxidant is genisten. In one

embodiment, the antioxidant is pycnogenol. In one embodiment, the antioxidant is niacinamide. In one embodiment, the antimicrobial composition comprises about 0.01 wt.% to about 0.5 wt.% of one or more antioxidants selected from the group consisting of ascorbic acid, palmitic acid, ascorbyl palmitate, α -tocopherol, idebenone, ubiquinone, ferulic acid, coenzyme Q10, lycopene, green tea, catechins, epigallocatechin 3-gallate (EGCG), green tea polyphenols (GTP), silymarin, coffeeberry, resveratrol, grape seed, pomegranate extracts, genisten, pycnogenol, and niacinamide. In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 0.3 wt.% of one or more antioxidants selected from the group consisting of ascorbic acid, palmitic acid, ascorbyl palmitate, α -tocopherol, idebenone, ubiquinone, ferulic acid, coenzyme Q10, lycopene, green tea, catechins, epigallocatechin 3-gallate (EGCG), green tea polyphenols (GTP), silymarin, coffeeberry, resveratrol, grape seed, pomegranate extracts, genisten, pycnogenol, and niacinamide. In one embodiment, the antimicrobial composition comprises about 0.3 wt.% to about 0.5 wt.% of one or more antioxidants selected from the group consisting of ascorbic acid, palmitic acid, ascorbyl palmitate, α -tocopherol, idebenone, ubiquinone, ferulic acid, coenzyme Q10, lycopene, green tea, catechins, epigallocatechin 3-gallate (EGCG), green tea polyphenols (GTP), silymarin, coffeeberry, resveratrol, grape seed, pomegranate extracts, genisten, pycnogenol, and niacinamide. In one embodiment, the antimicrobial composition comprises about 0.45 wt.% of one or more antioxidants selected from the group consisting of ascorbic acid, palmitic acid, ascorbyl palmitate, α -tocopherol, idebenone, ubiquinone, ferulic acid, coenzyme Q10, lycopene, green tea, catechins, epigallocatechin 3-gallate (EGCG), green tea polyphenols (GTP), silymarin, COFFEEBERRY, resveratrol, grape seed, pomegranate extracts, genisten, pycnogenol, and niacinamide. In one embodiment, the antimicrobial composition comprises about 0.05 wt.% of idebenone. In one embodiment, the antimicrobial composition comprises about 0.05 wt.% to about 1 wt.% of ubiquinone, for example about 0.05 wt.%, about 0.1 wt.%, about 0.15 wt.%, about 0.2 wt.%, about 0.25 wt.%, about 0.3 wt.%, about 0.35 wt.%, about 0.4 wt.%, about 0.45 wt.%, about 0.5 wt.%, about 0.55 wt.%, about 0.6 wt.%, about 0.65 wt.%, about 0.7 wt.%, about 0.75 wt.%, about 0.8 wt.%, about 0.85 wt.%, about 0.9 wt.%, about 0.95 wt.%, or about 1 wt.% of ubiquinone. In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 1 wt.% of ferulic acid, for example about 0.1 wt.%, about 0.15 wt.%, about 0.2 wt.%, about 0.25 wt.%, about 0.3 wt.%, about 0.35 wt.%, about 0.4 wt.%, about 0.45 wt.%, about 0.5 wt.%, about 0.55 wt.%, about 0.6 wt.%, about 0.65 wt.%, about 0.7 wt.%, about 0.75 wt.%, about

0.8 wt.%, about 0.85 wt.%, about 0.9 wt.%, about 0.95 wt.%, or about 1 wt.% of ferulic acid. In one embodiment, the antimicrobial composition comprises about 0.01 wt.% to about 0.5 wt.% of ascorbyl palmitate, about 0.01 wt.% to about 0.5 wt.% of α -tocopherol, and about 0.01 wt.% to about 0.5 wt.% of ascorbic acid. In one embodiment the antimicrobial composition comprises about 0.1 wt.% to about 0.3 wt.% of ascorbyl palmitate, about 0.1 wt.% to about 0.3 wt.% of α -tocopherol, and about 0.05 wt.% to about 0.2 wt.% of ascorbic acid. In one embodiment the antimicrobial composition comprises about 0.2 wt.% of ascorbyl palmitate, about 0.15 wt.% of α -tocopherol, and about 0.1 wt.% of ascorbic acid.

[0067] In one embodiment, the antimicrobial composition comprises one or more emollients such as a fully saturated triglyceride (*e.g.*, medium-chain triglycerides such as Crodamol GTCC, Croda International plc), myristyl myristate, isopropyl palmitate, and glycerin. In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 20 wt.% of an emollient, for example about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, about 5 wt.%, about 5.1 wt.%, about 5.2 wt.%, about 5.3 wt.%, about 5.4 wt.%, about 5.5 wt.%, about 5.6 wt.%, about 5.7 wt.%, about 5.8 wt.%, about 5.9 wt.%, about 6 wt.%, about 6.1 wt.%, about 6.2 wt.%, about 6.3 wt.%, about 6.4 wt.%, about 6.5 wt.%, about 6.6 wt.%, about 6.7 wt.%, about 6.8 wt.%, about 6.9 wt.%, about 7 wt.%, about 7.1 wt.%, about 7.2 wt.%, about 7.3 wt.%, about 7.4 wt.%, about 7.5 wt.%, about 7.6 wt.%, about 7.7 wt.%, about 7.8 wt.%, about 7.9 wt.%, about 8 wt.%, about 8.1 wt.%, about 8.2 wt.%, about 8.3 wt.%, about 8.4 wt.%, about 8.5 wt.%, about 8.6 wt.%, about 8.7 wt.%, about 8.8 wt.%, about 8.9 wt.%, about 9 wt.%, about 9.1 wt.%, about 9.2 wt.%, about 9.3 wt.%, about 9.4 wt.%, about 9.5 wt.%, about 9.6 wt.%, about 9.7 wt.%, about 9.8 wt.%, about 9.9 wt.%, about 10 wt.%, about 10.1 wt.%, about 10.2 wt.%, about 10.3 wt.%, about 10.4 wt.%, about 10.5 wt.%, about 10.6 wt.%, about 10.7 wt.%, about 10.8 wt.%, about 10.9 wt.%, about 11 wt.%, about 11.1 wt.%, about 11.2 wt.%, about 11.3 wt.%, about 11.4 wt.%, about 11.5 wt.%, about

11.6 wt.%, about 11.7 wt.%, about 11.8 wt.%, about 11.9 wt.%, about 12 wt.%, about 12.1 wt.%, about 12.2 wt.%, about 12.3 wt.%, about 12.4 wt.%, about 12.5 wt.%, about 12.6 wt.%, about 12.7 wt.%, about 12.8 wt.%, about 12.9 wt.%, about 13 wt.%, about 13.1 wt.%, about 13.2 wt.%, about 13.3 wt.%, about 13.4 wt.%, about 13.5 wt.%, about 13.6 wt.%, about 13.7 wt.%, about 13.8 wt.%, about 13.9 wt.%, about 14 wt.%, about 14.1 wt.%, about 14.2 wt.%, about 14.3 wt.%, about 14.4 wt.%, about 14.5 wt.%, about 14.6 wt.%, about 14.7 wt.%, about 14.8 wt.%, about 14.9 wt.%, about 15 wt.%, about 15.1 wt.%, about 15.2 wt.%, about 15.3 wt.%, about 15.4 wt.%, about 15.5 wt.%, about 15.6 wt.%, about 15.7 wt.%, about 15.8 wt.%, about 15.9 wt.%, about 16 wt.%, about 16.1 wt.%, about 16.2 wt.%, about 16.3 wt.%, about 16.4 wt.%, about 16.5 wt.%, about 16.6 wt.%, about 16.7 wt.%, about 16.8 wt.%, about 16.9 wt.%, about 17 wt.%, about 17.1 wt.%, about 17.2 wt.%, about 17.3 wt.%, about 17.4 wt.%, about 17.5 wt.%, about 17.6 wt.%, about 17.7 wt.%, about 17.8 wt.%, about 17.9 wt.%, about 18 wt.%, about 18.1 wt.%, about 18.2 wt.%, about 18.3 wt.%, about 18.4 wt.%, about 18.5 wt.%, about 18.6 wt.%, about 18.7 wt.%, about 18.8 wt.%, about 18.9 wt.%, about 19 wt.%, about 19.1 wt.%, about 19.2 wt.%, about 19.3 wt.%, about 19.4 wt.%, about 19.5 wt.%, about 19.6 wt.%, about 19.7 wt.%, about 19.8 wt.%, about 19.9 wt.%, or about 20 wt.% of an emollient. In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 5 wt.% of any one emollient. In one embodiment, the one or more emollients are selected from the group consisting of medium-chain triglycerides (*e.g.*, Crodamol GTCC, Croda International plc), myristyl myristate, isopropyl palmitate, and glycerin.

[0068] In one embodiment, the antimicrobial composition comprises medium-chain triglycerides (*e.g.*, Crodamol GTCC), myristyl myristate, isopropyl palmitate and glycerin in a combined amount of about 0.5 wt. to about 20 wt.%. In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 5 wt.% of medium-chain triglycerides (*e.g.*, Crodamol GTCC), for example about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%,

about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, or about 5 wt.% of medium-chain triglycerides (*e.g.*, Crodamol GTCC). In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 5 wt.% of myristyl myristate, for example about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, or about 5 wt.% of myristyl myristate.

[0069] In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 8 wt.% of isopropyl palmitate, for example about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, about 5 wt.%, about 5.1 wt.%, about 5.2 wt.%, about 5.3 wt.%, about 5.4 wt.%, about 5.5 wt.%, about 5.6 wt.%, about 5.7 wt.%, about 5.8 wt.%, about 5.9 wt.%, about 6 wt.%, about 6.1 wt.%, about 6.2 wt.%, about 6.3 wt.%, about 6.4 wt.%, about 6.5 wt.%, about 6.6 wt.%, about 6.7 wt.%, about 6.8 wt.%, about 6.9 wt.%, about 7 wt.%, about 7.1 wt.%, about 7.2 wt.%, about 7.3 wt.%, about 7.4 wt.%, about 7.5 wt.%, about 7.6 wt.%, about 7.7 wt.%, about 7.8 wt.%, about 7.9 wt.%, or about 8 wt.% of isopropyl palmitate.

[0070] In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 5 wt.% of glycerin, for example about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about

1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, or about 5 wt.% of glycerin. In one embodiment, the antimicrobial composition comprises about 2 wt.% of medium-chain triglycerides (*e.g.*, Crodamol GTCC), about 2 wt.% of myristyl myristate (*e.g.*, Crodamol MM, Croda International plc), about 4 wt.% of isopropyl palmitate (*e.g.*, Crodamol IPP, Croda International plc), and about 1 wt.% of glycerin.

[0071] In one embodiment, the antimicrobial composition comprises a preservative such as phenoxyethanol. In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 5 wt.% of a preservative, for example about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, or about 5 wt.% of a preservative. In one embodiment, the preservative is phenoxyethanol. In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 5 wt.% of phenoxyethanol. In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 2 wt.% of phenoxyethanol. In one embodiment, the antimicrobial composition comprises about 1 wt.% of phenoxyethanol.

[0072] In one embodiment, the antimicrobial composition comprises one or more thickeners, such as a cross-linked polymer (*e.g.*, a cross-linked acrylic acid polymer such as carbomer, available commercially as Carbopol ETD2020NF, Lubrizol Corp.), a polysaccharide (*e.g.*, a xanthan gum such as CPKelco's Keltrol 11K). In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 5 wt.% of one or more

thickeners, for example about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, or about 5 wt.% of one or more thickeners. In one embodiment, the one or more thickeners is one or more of a cross-linked acrylic acid polymer and a polysaccharide. In one embodiment, the one or more thickeners are Carbopol ETD2020NF and Keltrol 11K. In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 5 wt.% of Carbopol ETD2020NF and about 0.1 wt.% to about 5 wt.% of Keltrol 11K. In one embodiment, the antimicrobial composition comprises about 0.5 wt.% to about 1 wt.% of Carbopol ETD2020NF and about 0.2 wt.% to about 1 wt.% of Keltrol 11K. In one embodiment, the antimicrobial composition comprises about 0.8 wt.% of Carbopol ETD2020NF and about 0.4 wt.% of Keltrol 11K.

[0073] In one embodiment, the antimicrobial composition comprises one or more texturizers such as a lecithin (*e.g.*, a liquid soy lecithin such as Leciprime 1400 IPM, Cargill, Inc.). In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 5 wt.% of one or more texturizers, for example about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 1.1 wt.%, about 1.2 wt.%, about 1.3 wt.%, about 1.4 wt.%, about 1.5 wt.%, about 1.6 wt.%, about 1.7 wt.%, about 1.8 wt.%, about 1.9 wt.%, about 2 wt.%, about 2.1 wt.%, about 2.2 wt.%, about 2.3 wt.%, about 2.4 wt.%, about 2.5 wt.%, about 2.6 wt.%, about 2.7 wt.%, about 2.8 wt.%, about 2.9 wt.%, about 3 wt.%, about 3.1 wt.%, about 3.2 wt.%, about 3.3 wt.%, about 3.4 wt.%, about 3.5 wt.%, about 3.6 wt.%, about 3.7 wt.%, about 3.8 wt.%, about 3.9 wt.%, about 4 wt.%, about 4.1 wt.%, about 4.2 wt.%, about 4.3 wt.%, about 4.4 wt.%, about 4.5 wt.%, about 4.6 wt.%, about 4.7 wt.%, about 4.8 wt.%, about 4.9 wt.%, or about 5 wt.% of one or more texturizers. In one embodiment, the one or more texturizers comprise Leciprime 1400 IPM. In one embodiment, the antimicrobial composition comprises about 0.1 wt.% to about 5 wt.% of Leciprime 1400

IPM. In one embodiment, the antimicrobial composition comprises about 0.2 wt.% to about 1 wt.% of Leciprime 1400 IPM. In one embodiment, the antimicrobial composition comprises about 0.5 wt.% of Leciprime 1400 IPM.

[0074] In one embodiment, the antimicrobial composition comprises one or more fragrances. In one embodiment, the antimicrobial composition comprises about 0.01 wt.% to about 0.5 wt.% of one or more fragrances, for example about 0.01 wt.%, about 0.02 wt.%, about 0.03 wt.%, about 0.04 wt.%, about 0.05 wt.%, about 0.06 wt.%, about 0.07 wt.%, about 0.08 wt.%, about 0.09 wt.%, about 0.1 wt.%, about 0.11 wt.%, about 0.12 wt.%, about 0.13 wt.%, about 0.14 wt.%, about 0.15 wt.%, about 0.16 wt.%, about 0.17 wt.%, about 0.18 wt.%, about 0.19 wt.%, about 0.2 wt.%, about 0.21 wt.%, about 0.22 wt.%, about 0.23 wt.%, about 0.24 wt.%, about 0.25 wt.%, about 0.26 wt.%, about 0.27 wt.%, about 0.28 wt.%, about 0.29 wt.%, about 0.3 wt.%, about 0.31 wt.%, about 0.32 wt.%, about 0.33 wt.%, about 0.34 wt.%, about 0.35 wt.%, about 0.36 wt.%, about 0.37 wt.%, about 0.38 wt.%, about 0.39 wt.%, about 0.4 wt.%, about 0.41 wt.%, about 0.42 wt.%, about 0.43 wt.%, about 0.44 wt.%, about 0.45 wt.%, about 0.46 wt.%, about 0.47 wt.%, about 0.48 wt.%, about 0.49 wt.%, or about 0.5 wt.% of one or more fragrances.

[0075] In one embodiment, the antimicrobial composition comprises: about 0.5 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 0.5 wt.% to about 5 wt.% of one or more surfactants; about 0.5 wt.% to about 5 wt.% of one or more emulsifiers; about 0.05 wt.% to about 5 wt.% of one or more stabilizers; about 0.01 wt.% to about 2 wt.% of one or more antioxidants; about 0.5 wt.% to about 20 wt.% of one or more emollients; about 0.1 wt.% to about 5 wt.% of one or more preservatives; about 0.1 wt.% to about 5 wt.% of one or more thickeners; about 0.1 wt.% to about 5 wt.% of one or more texturizers; and about 0.01 wt.% to about 0.5 wt.% of one or more fragrances.

[0076] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally

about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 1 wt.% to about 2 wt.% of one or more surfactants; about 1 wt.% to about 2 wt.% of one or more emulsifiers; about 0.1 wt.% to about 1 wt.% of one or more stabilizers; about 0.1 wt.% to about 1 wt.% of one or more antioxidants; about 5 wt.% to about 15 wt.% of one or more emollients; about 0.5 wt.% to about 2 wt.% of one or more preservatives; about 0.5 wt.% to about 2 wt.% of one or more thickeners; about 0.1 wt.% to about 2 wt.% of one or more texturizers; and about 0.01 wt.% to about 0.1 wt.% of one or more fragrances.

[0077] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 1.65 wt.% of one or more surfactants; about 1.35 wt.% of one or more emulsifiers; about 0.5 wt.% of one or more stabilizers; about 0.45 wt.% of one or more antioxidants; about 9 wt.% of one or more emollients; about 1 wt.% of one or more preservatives; about 1.2 wt.% of one or more thickeners; about 0.5 wt.% of one or more texturizers; and about 0.05 wt.% of one or more fragrances.

[0078] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 0.5 wt.% to about 5 wt.% of Steareth-2; about 0.5 wt.% to about 5 wt.% of Steareth-21; about 0.1 wt.% to about 5 wt.% of cetyl alcohol; about 0.01 wt.% to about 2 wt.% of a combination of medium-chain triglycerides, myristyl myristate, isopropyl palmitate, and/or glycerin; about 0.5 wt.% to about 20 wt.% of one or more emollients; about 0.1 wt.% to about 5 wt.% of phenoxyethanol; about 0.1 wt.% to about 5 wt.% of a combination of carbomer and/or

xanthan gum; about 0.1 wt.% to about 5 wt.% of liquid soy lecithin; and about 0.01 wt.% to about 0.5 wt.% of one or more fragrances.

[0079] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 1 wt.% to about 2 wt.% of Steareth-2; about 1 wt.% to about 2 wt.% of Steareth-21; about 0.1 wt.% to about 1 wt.% of cetyl alcohol; about 0.1 wt.% to about 1 wt.% of a combination of ascorbyl palmitate, α -tocopherol, and ascorbic acid; about 5 wt.% to about 15 wt.% of a combination of medium-chain triglycerides, myristyl myristate, isopropyl palmitate, and/or glycerin; about 0.5 wt.% to about 2 wt.% of phenoxyethanol; about 0.5 wt.% to about 2 wt.% of a combination of carbomer and/or xanthan gum; about 0.1 wt.% to about 2 wt.% of liquid soy lecithin; and about 0.01 wt.% to about 0.1 wt.% of one or more fragrances.

[0080] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 1.65 wt.% of Steareth-2; about 1.35 wt.% of Steareth-21; about 0.5 wt.% of cetyl alcohol; about 0.2 wt.% of ascorbyl palmitate; about 0.15 wt.% of α -tocopherol; about 0.1 wt.% of ascorbic acid; about 2 wt.% of medium-chain triglycerides; about 2 wt.% of myristyl myristate; about 4 wt.% of isopropyl palmitate; about 1 wt.% of glycerin; about 1 wt.% of phenoxyethanol, about 0.8 wt.% of carbomer; about 0.4 wt.% of xanthan gum; about 0.5 wt.% of liquid soy lecithin; and about 0.05 wt.% of one or more fragrances.

[0081] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial

composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 0.5 wt.% to about 5 wt.% of BRIJ S2; about 0.5 wt.% to about 5 wt.% of BRIJ S721; about 0.1 wt.% to about 5 wt.% of Crodacol C95 EP; about 0.01 wt.% to about 2 wt.% of a combination of Crodamol GTCC, Crodamol MM, Crodamol IPP, and/or glycerin; about 0.5 wt.% to about 20 wt.% of one or more emollients; about 0.1 wt.% to about 5 wt.% of phenoxyethanol; about 0.1 wt.% to about 5 wt.% of a combination of Carbopol ETD2020NF and/or Keltrol 11K; about 0.1 wt.% to about 5 wt.% of Leciprime 1400 IPM; and about 0.01 wt.% to about 0.5 wt.% of Mild Care 345 fragrance.

[0082] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 1 wt.% to about 2 wt.% of BRIJ S2; about 1 wt.% to about 2 wt.% of BRIJ S721; about 0.1 wt.% to about 1 wt.% of Crodacol C95 EP; about 0.1 wt.% to about 1 wt.% of a combination of ascorbyl palmitate, α -tocopherol, and ascorbic acid; about 5 wt.% to about 15 wt.% of a combination of Crodamol GTCC, Crodamol MM, Crodamol IPP, and/or glycerin; about 0.5 wt.% to about 2 wt.% of phenoxyethanol; about 0.5 wt.% to about 2 wt.% of a combination of Carbopol ETD2020NF and/or Keltrol 11K; about 0.1 wt.% to about 2 wt.% of Leciprime 1400 IPM; and about 0.01 wt.% to about 0.1 wt.% of Mild Care 345 fragrance.

[0083] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 1 wt.% to about 2 wt.% of BRIJ S2; about 1 wt.% to about 2 wt.% of BRIJ S721; about 0.1 wt.% to about 1 wt.% of Crodacol C95 EP; about 0.1 wt.% to about 1 wt.% of a combination of ascorbyl palmitate, α -tocopherol, and ascorbic acid; about 5 wt.% to about

15 wt.% of a combination of Crodamol GTCC, Crodamol MM, Crodamol IPP, and/or glycerin; about 0.5 wt.% to about 2 wt.% of phenoxyethanol; about 0.5 wt.% to about 2 wt.% of a combination of Carbopol ETD2020NF and/or Keltrol 11K; about 0.1 wt.% to about 5 wt.% of Leciprime 1400 IPM; and about 0.01 wt.% to about 0.1 wt.% of Mild Care 345 fragrance.

[0084] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.5 mg to about 10 mg of neomycin sulfate per gram of antimicrobial composition; optionally about 1,000 units to about 20,000 units of polymyxin B per gram of antimicrobial composition; optionally about 100 units to about 800 units of bacitracin zinc per gram of antimicrobial composition; optionally about 1 mg to about 20 mg of pramoxine HCl; about 1.65 wt.% of BRIJ S2; about 1.35 wt.% of BRIJ S721; about 0.5 wt.% of Crodacol C95 EP; about 0.2 wt.% of ascorbyl palmitate; about 0.15 wt.% of α -tocopherol, about 0.1 wt.% of ascorbic acid; about 2 wt.% Crodamol GTCC; about 2 wt.% of Crodamol MM; about 4 wt.% of Crodamol IPP; about 1 wt.% of glycerin; about 1 wt.% of phenoxyethanol, about 0.8 wt.% of Carbopol ETD2020NF; about 0.4 wt.% of Keltrol 11K; about 0.5 wt.% of Leciprime 1400 IPM; and about 0.05 wt.% of Mild Care 345 fragrance.

[0085] In one embodiment, the antimicrobial composition comprises: about 0.1 wt.% to about 20 wt.% of one or more of DGLA, 15-OHEPA, and 15-HETrE; optionally about 0.01 % to about 1.0% mg of triclosan in an antimicrobial composition;

[0086] A composition for use in accordance with the disclosure can be formulated as one or more dosage units. The terms “dose unit” and “dosage unit” herein refer to a portion of an antimicrobial composition that contains an amount of a therapeutic agent suitable for a single administration to provide a therapeutic effect. Such dosage units may be administered one to a plurality (*i.e.* 1 to about 10, 1 to 8, 1 to 6, 1 to 4 or 1 to 2) of times per day, or as many times as needed to elicit a therapeutic response.

[0087] In one embodiment, a composition including, for example, an antimicrobial composition, as disclosed herein is formulated as an aerosol, a gel, an ointment, a lotion, a cream, a gel stick, a liniment, a paste or a spray.

[0088] Such formulations may be stable and comprise an amount (*e.g.*, a therapeutically effective amount) of DGLA, 15-OHEPA, 15-HETrE in combination with one or more antibacterial agents selected from the group consisting of: nicotinamide, triclosan, metronidazole, neomycin sulfate, polymyxin B and bacitracin zinc.

[0089] The present disclosure also provides the disclosed compositions or formulations as a component in a product for use in the treatment of skin or gingival infections. In one embodiment, the product comprises a container and an antimicrobial composition comprising a therapeutically effective amount of DGLA, 15-OHEPA, 15-HETrE, or a combination thereof. In one embodiment, the antimicrobial composition comprises from about 0.1 wt.% to about 20 wt.% of DGLA, 15-OHEPA, 15-HETrE, or a combination thereof. In one embodiment, the product comprises an antimicrobial composition as disclosed herein.

Pharmacokinetics/Pharmacodynamic

[0090] The pharmacokinetics and /or pharmacodynamics of the compositions comprising DGLA, 15-OHEPA, or 15-HETrE as disclosed herein may be determined by any method known in the art.

[0091] In an embodiment, the pharmacokinetics of a composition comprising DGLA, 15-OHEPA, or 15-HETrE as disclosed herein may be examined using a skin blister technique (*see, e.g.*, Tope, *Dermatol Surg* 25:348:52 (1999)) to determine the amount of various constituents of the composition that are absorbed through the skin. In an exemplary method, a defined area of the skin is contacted with one or more doses of the compositions at one or more time intervals. Next, epidermal blisters may be made by application of controlled suction to an area of the skin (*see, e.g.*, Kiistala (1968) *J. Investig. Dermatol.* 50:129–137; Kiistala, et al. (1964) *Lancet* 1964:1444–1445; and Schreiner, et al. (1978) *Scand. J. Infect. Dis.* 14(Suppl.):233–237). Prior to the start of forming a blister on an area of the skin, the area may be hydrated with a warm compress and/or swabbed with 70% isopropanol. Next, a suction apparatus may be placed on the area of the skin and controlled suction applied to with an electric vacuum pump. The vacuum may be increased slowly over a period of time (*e.g.*, 1 min) up to a maximum negative pressure sufficient to form a blister (*e.g.*, 0.3 kg/cm² (3.104 Pa)). The pressure may be maintained for several hours (*e.g.*, 2 to 3 h) until half-spherical blisters are formed. As soon as the blisters appeared, the vacuum may be released, and the suction chamber apparatus carefully removed without breaking the blister. The blister fluid

(*e.g.*, 50-500 μ L) may then be aspirated and examined. Samples of blister fluid may be stored at -70°C until analysis. The concentration of DGLA, 15-OHEPA, or 15-HETrE or other constituents from the disclosed compositions may be determined in blister fluid samples by any method known in the art including, for example, gas chromatography MS (GC/MS), or reverse-phase high-performance liquid chromatography (HPLC).

[0092] The compositions comprising DGLA as provided herein deliver DGLA at a mean flux rate of from about 0.1 ng to about 1 mg/cm²/hr at about 2, 4, 6, 8, 12, 24, 48 or 72 hours after administration. The compositions comprising 15-OHEPA as provided herein deliver 15-OHEPA at a mean flux rate of from about 0.1 ng to about 1 mg/cm²/hr at about 2, 4, 6, 8, 12, 24, 48 or 72 hours after administration. The compositions comprising 15-HETrE as provided herein deliver 15-HETrE at a mean flux rate of from about 0.1 ng to about 1 mg/cm²/hr at about 2, 4, 6, 8, 12, 24, 48 or 72 hours after administration.

Methods of Treatment of Diseases and/or Disorders

[0093] The compositions and formulations disclosed herein may be used in the prevention and treatment of diseases and/or disorders including, for example, disease and/or disorders of the skin and gingiva such as contusions, wounds, burns, sores, ulcers, scrapes, incisions, lacerations, skin infection, gingivitis or periodontal disease.

[0094] Methods are provided herein for treating or preventing skin or gingival infections in a subject in need thereof comprising administering to the subject an antimicrobial composition comprising an effective amount including, for example, a therapeutically effective amount (*e.g.*, 0.1 wt.% to about 20 wt.%) of DGLA, 15-OHEPA, or 15-HETrE as described herein.

[0095] The term “skin infection” herein refers to any disease or disorder of the skin that presents with one or more occurring or reoccurring symptoms such as erythema, warmth, swelling, tenderness, pain, ulcers, lesion(s), nodules, fever, scaling, plaques, papules, pustules, cysts, and the like. Non-limiting examples of skin infections include cellulitis; erysipelas; impetigo; folliculitis; furuncles; carbuncles; secondarily infected dermatoses such as atopic dermatitis, allergic contact dermatitis and psoriasis; secondarily infected traumatic lesions; acne; and other skin disorders associated with infectious pathogens.

[0096] In one embodiment, the present disclosure provides a method of treating or preventing a skin or gingival infection in a subject in need thereof. In one embodiment, the method comprises administering to the subject an antimicrobial composition as disclosed herein, for example a antimicrobial comprising a therapeutically effective amount of DGLA, 15-OHEPA, 15-HETrE, or a combination thereof, along with one or more antibiotic agents. In one embodiment, the antimicrobial composition comprises from about 0.1 wt.% to about 20 wt.% of DGLA, 15-OHEPA, 15-HETrE, or a combination thereof.

[0097] In one embodiment, the present disclosure provides a method of inhibiting one or more skin or oral pathogens including, for example, its growth, colonization and/or infection in a subject in need thereof. In one embodiment, the method comprises contacting a skin or oral pathogen with a composition as disclosed herein, for example a composition comprising one or more of DGLA, 15-OHEPA, and 15-HETrE and one or more antibiotic agents. In one embodiment, the skin or gingival pathogen is one or more of: *Staphylococcus* spp. (including, for example, *S. aureus*, *S. lugdunensis*, *S. schleiferi* and other coagulase-negative *Staphylococcus* spp.), *Streptococcus* spp. (including, for example, β -haemolytic *Streptococci*, Viridans group *Streptococci*, non-haemolytic *Streptococci*, and *Streptococcus milleri* group), *Corynebacterium* spp., *Bacillus* spp. (including, for example, *B. anthracis* and *B. cereus*), *Acinetobacter* spp., *Moraxella* spp., *Peptostreptococcus* spp., *Propionibacterium* spp., (including, for example, *P. Acnes*), *Candida* spp., *Pseudomonas* spp. and other non-fermentative bacilli (including, for example, *P. aeruginosa*), Dermatophytes, Enterobacteriaceae, *Pasturella multocida*, *Mycobacterium* spp., *Haemophilus* spp., *Nocardia* spp., *Erysipelothrix rhusiopathiae*, *Vibrio* spp., *Enterococcus* spp., *Eikenella corrodens*, anaerobes, *Corynebacterium* spp., *Actinomyces* spp., and/or fungal pathogens. In one embodiment, the composition comprises from about 0.1 wt.% to about 20 wt.% of DGLA, 15-OHEPA, 15-HETrE, or a combination thereof.

[0098] In one embodiment, the method further comprises washing an affected area of the skin (and/or to an area of the skin that is generally prone to development of a skin infection) prior to administering the antimicrobial composition. As used herein, the term “washing” refers generally to any method known to those of skill in the art for cleansing the skin, exfoliating the skin, removing dirt, oil, dead skin cells and the like from the skin, etc.

[0099] In one embodiment, the method comprises topically administering the antimicrobial composition to an area of the skin or oral cavity infected by a pathogen and/or to an area of the skin or gingiva that is generally prone to development of an infection and/or previously had an infection.

[0100] In one embodiment, the method comprises administering an antimicrobial composition as disclosed herein once per day, twice per day, three times per day, or more than three times per day.

[0101] In one embodiment, upon treatment in accordance with the present disclosure, for example over a period of about 1 to about 200 weeks, about 1 to about 100 weeks, about 1 to about 80 weeks, about 1 to about 50 weeks, about 1 to about 40 weeks, about 1 to about 20 weeks, about 1 to about 15 weeks, about 1 to about 12 weeks, about 1 to about 10 weeks, about 1 to about 5 weeks, about 1 to about 2 weeks or about 1 week, the treated area of the skin or gingiva comprises about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or greater than about 90% fewer lesions than before treatment.

[0102] As used herein, “treating” or “treatment” of a disease, disorder, or condition includes at least partially: (1) preventing the disease, disorder, or condition, *i.e.* causing the clinical symptoms of the disease, disorder, or condition not to develop in a mammal that is exposed to or predisposed to the disease, disorder, or condition but does not yet experience or display symptoms of the disease, disorder, or condition; (2) inhibiting the disease, disorder, or condition, *i.e.*, arresting or reducing the development of the disease, disorder, or condition or its clinical symptoms; or (3) relieving the disease, disorder, or condition, *i.e.*, causing regression of the disease, disorder, or condition or its clinical symptoms. The term “prevention” in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.

[0103] An “effective amount,” as used herein, refers to the amount of an active composition that is required to confer a therapeutic effect on the subject. A “therapeutically effective amount,” as used herein, refers to a sufficient amount of an agent or a compound being

administered which will relieve to some extent one or more of the symptoms of the disease, disorder, or condition being treated. In some embodiments, the result is a reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, in some embodiments, an “effective amount” for therapeutic uses is the amount of the composition including a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms without undue adverse side effects. In some embodiments, an appropriate “effective amount” in any individual case is determined using techniques, such as a dose escalation study. The term “therapeutically effective amount” includes, for example, a prophylactically effective amount. In other embodiments, an “effective amount” of a compound disclosed herein, such as DGLA, 15-OHEPA, and/or 15-HETrE, is an amount effective to achieve a desired pharmacologic effect or therapeutic improvement without undue adverse side effects. In other embodiments, it is understood that “an effect amount” or “a therapeutically effective amount” varies from subject to subject, due to variation in metabolism, age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician. The term “pharmaceutically acceptable” in the present context means that the substance in question does not produce unacceptable toxicity to the subject or interaction with other components of the composition.

[0104] In another embodiment, the present disclosure provides a method of slowing progression of or promoting regression of a skin or gingival infection in a subject in need thereof, comprising administering to a subject in need thereof one or more compositions as disclosed herein.

[0105] In one embodiment, the present disclosure provides a method of reducing or preventing side effects associated with topical administration of neomycin sulfate. Administration of high doses of neomycin sulfate has been associated with redness and irritation of the skin, allergic reactions (*e.g.*, rash, hives, itching, difficult breathing, chest tightness, swelling of the mouth, face, lips or tongue), bloody stool, dizziness, hearing loss, muscle twitching, ringing in the ears, seizures, tingling or numbness of the skin, vaginal irritation or discharge, and stomach pains or cramps. In one embodiment, a method of reducing side effects associated with topical administration of neomycin sulfate comprises discontinuing administration of a first antimicrobial composition comprising neomycin sulfate and administering to a subject a second antimicrobial composition as disclosed herein.

In one embodiment, the second antimicrobial composition includes an amount of neomycin sulfate that is less than the amount of neomycin sulfate in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes an amount of neomycin sulfate that is about equal to or equal to the amount of neomycin sulfate in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes an amount of neomycin sulfate that is more than the amount of neomycin sulfate in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes no neomycin sulfate, essentially no neomycin sulfate, or substantially no neomycin sulfate.

[0106] In one embodiment, the present disclosure provides a method of reducing or preventing side effects associated with topical administration of polymyxin B.

Administration of high doses of polymyxin B has been associated with redness and irritation of the skin, severe allergic reactions (*e.g.*, rash, hives, itching, difficulty breathing, chest tightness, swelling of the mouth, face, lips, or tongue), changes in the amount of urine, changes in hearing or ringing in the ears, dizziness, drowsiness, flushing of the face, loss of coordination, mental or mood changes (*e.g.*, irritability), severe headaches, stiff neck, tingling or numbness in the mouth, hands, or feet, unusual weakness, unusually fast heartbeat, and changes in vision. In one embodiment, a method of reducing side effects associated with topical administration of polymyxin B comprises discontinuing administration of a first antimicrobial composition comprising polymyxin B and administering to a subject a second antimicrobial composition as disclosed herein. In one embodiment, the second antimicrobial composition includes an amount of polymyxin B that is less than the amount of polymyxin B in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes an amount of polymyxin B that is about equal to or equal to the amount of polymyxin B in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes an amount of polymyxin B that is more than the amount of polymyxin B in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes no polymyxin B, essentially no polymyxin B, or substantially no polymyxin B.

[0107] In one embodiment, the present disclosure provides a method of reducing or preventing side effects associated with topical administration of bacitracin zinc.

Administration of high doses of bacitracin zinc has been associated with redness and

irritation of the skin, severe allergic reactions (*e.g.*, rash, hives, itching, difficulty breathing, chest tightness, swelling of the mouth, face, lips, or tongue), changes in vision, continued redness, burning, or itching, eye pain, and secondary infection. In one embodiment, a method of reducing side effects associated with topical administration of bacitracin zinc comprises discontinuing administration of a first antimicrobial composition comprising bacitracin zinc and administering to a subject a second antimicrobial composition as disclosed herein. In one embodiment, the second antimicrobial composition includes an amount of bacitracin zinc that is less than the amount of bacitracin zinc in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes an amount of bacitracin zinc that is about equal to or equal to the amount of bacitracin zinc in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes an amount of bacitracin zinc that is more than the amount of bacitracin zinc in the first antimicrobial composition. In one embodiment, the second antimicrobial composition includes no bacitracin zinc, essentially no bacitracin zinc, or substantially no bacitracin zinc.

[0108] In one embodiment, the present disclosure provides a method of reducing scarring in at least a portion of a subject's skin. In one embodiment, the method comprises administering to the subject a therapeutically effective amount of an antimicrobial composition as disclosed herein. In one embodiment, the amount of scarring per square inch for a given affected area of the subject's skin after administration of an antimicrobial composition as disclosed herein is less than, or substantially less than the amount of scarring present in the same area of skin before administration of an antimicrobial composition as disclosed herein. In one embodiment, treatment according to the present method results in a 10% reduction, about a 20% reduction, about a 30% reduction, about a 40% reduction, about a 50% reduction, about a 60% reduction, about a 70% reduction, about a 80% reduction, about a 90% reduction, or more than a 90% reduction in scarring for a given area of the subject's skin. In one embodiment, the reduction in scarring occurs within about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months, about 18 months, about 19 months, about 20 months, about 21 months, about 22 months, about 23 months, or about 24 months of the initiation of the treatment method.

[0109] The present disclosure also provides methods of improving the antimicrobial activity of an agent used in the treatment of acne. The term “antimicrobial agent” includes antibiotics and antifungals. More specifically, “antimicrobial agents” may include neomycin sulfate, polymyxin B, bacitracin zinc, β -lactams (*e.g.*, ampicillin, amoxicillin, imipenem, meropenem), carbapenems, cephalosporins (*e.g.*, cephalexin, cephalothin, cefalozin, cefuroxime, cefotaxime, ceftazidime), fluoroquinolones, oxazolidinones, lincosamides, metronidazole, macrolide antibiotics (*e.g.*, clindamycin, erythromycin), quinolone antibiotics (*e.g.*, levofloxacin, ciprofloxacin), penicillins, glycopeptides (*e.g.*, vancomycin), aminoglycosides (*e.g.*, neomycin, gentamicin, tobramycin), trimethoprim/sulfamethoxazole (also known as co-trimoxazole or TMP/SMX), triclosan, doxycycline and tetracycline. In one embodiment, the method comprises adding an antimicrobial comprising one or more of DGLA, 15-OHEPA, and 15-HETrE to the agent. In one embodiment, the agent is one in which no previous antimicrobial activity was appreciated. In one embodiment, the antimicrobial composition is an antimicrobial composition as disclosed herein, for example an antimicrobial composition comprising from about 0.1 wt.% to about 20 wt.% of DGLA, 15-OHEPA, 15-HETrE, or a combination thereof.

[0110] Also disclosed is a method of treating or preventing a microbial infection comprising administering to a subject in need thereof a pharmaceutical composition comprising 15-HETrE;

[0111] Also disclosed is a method of minimizing or preventing scarring comprising administering to a wound of a subject a pharmaceutical composition comprising 15-HETrE.

[0112] Also disclosed is a pharmaceutical composition comprising 15-HETrE for use in treatment or prevention of a microbial infection.

[0113] Also disclosed is a pharmaceutical composition comprising 15-HETrE for minimizing or preventing scarring.

[0114] Also disclosed is a pharmaceutical composition comprising 15-HETrE for use in wound healing.

[0115] Also disclosed is a pharmaceutical composition of any one of paragraphs 0112 - 0114 comprising about 0.1 wt.% to about 20 wt.% of 15-HETrE and one or more excipients

[0116] Without further description, it is believed that one of ordinary skill in the art may, using the preceding description and the following illustrative examples, make and utilize the agents of the present disclosure and practice the claimed methods. The following working examples are provided to facilitate the practice of the present disclosure, and are not to be construed as limiting in any way the remainder of the disclosure.

EXAMPLES

Example 1: Effect of Various Compounds on the Growth of *P. Acnes*

[0117] Several compounds including fatty acids such as DGLA, 15-OHEPA, and 15-HETrE were tested to determine their capacity to inhibit the growth of *P. acnes*. In an exemplary method, an agar dilution method was used to determine the minimum inhibitory concentration (MIC) of each tested compound. Briefly, the agar dilution method involved preparing a series of concentrations of each compound (*e.g.*, nicotinamide, benzoyl peroxide, adapalene, metronidazole, DGLA, 15-OHEPA, and 15-HETrE) in a Reinforced Clostridial Agar (RCA) media that facilitates growth of *P. acnes* under anaerobic conditions. An inoculum of *P. acnes* was prepared by incubation of *P. acnes* for approximately seven days at 35-37°C to achieve a ≥ 1.0 OD₆₀₀ inoculum of *P. acnes* in RCM broth. A portion of this inoculum was then added to the surface of each plate as a 10µL spot and incubated at 35-37°C for 72 hours or more. Growth of *P. acnes* was then observed and compared to control plates in which no compound has been added, and positive inhibition plates prepared with erythromycin. The growth profile of each colony (spot) was characterized as per the following index: (+++) confluent growth (comparable to control); (++) less confluent growth; (+) marked reduction in growth to multiple tiny, single colonies; and (-) no growth present. The growth of *P. acnes* in the presence of nicotinamide, benzoyl peroxide, adapalene, metronidazole, DGLA, 15-OHEPA, and 15-HETrE was determined with varying concentrations of the compound (see, Table 2). Next, the MIC was determined as the concentration at which a marked reduction (+) occurs in the appearance of growth on the test plate (as per Clinical and Laboratory Standards Institute M11-A7).

Table 2: Effect of Various Compounds on Growth of *P. Acnes*.

Nicotinamide					Benzoyl Peroxide:				
Nicotinamide [mg/mL]	Growth Index (+++ , ++ , + , -)			Growth Avg	BPO [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
1	+++	+++	+++	+++	0.2	+++	+++	+++	+++
5	+++	+++	+++	+++	0.4	+++	+++	+++	+++
10	++	++	++	++	0.6	++	+++	++	++
15	-	+	+	+	0.8	+	+	+	+
25	-	-	-	-	1.0	-	-	-	-
Adapalene:					Metronidazole:				
Adapalene [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg.	Metronidazole [mg/mL]	Growth Index (+++ , ++ , + , -)			Growth Avg
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.2	+++	+++	+++	+++
0.4	+++	+++	+++	+++	0.4	+++	+++	+++	+++
0.6	++	++	+++	++	0.6	+++	+++	+++	+++
0.8	++	++	++	++	0.8	+++	+++	+++	+++
					1.0	+++	++	+++	+++
DGLA:					15-OHEPA:				
DGLA [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg.	15-OHEPA [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg.
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.010	+++	+++	+++	+++
0.4	+++	+++	+++	+++	0.025	+++	+++	+++	+++
0.6	++	-	++	+	0.050	+++	+++	+++	+++
0.8	++	+	+	+	0.075	+	+	+	+
1.0	+	+	+	+	0.1	-	-	-	-
15-HETrE:									
15-HETrE [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg.					
	Plate 1	Plate 2	Plate 3						
0.00001	+++	+++	+++	+++					
0.0001	+++	+++	+++	+++					
0.001	+++	+++	+++	+++					
0.01	++	+++	++	++					
0.05	-	-	-	-					

[0118] The MIC for DGLA was determined to be >0.4 , ≤ 0.6 . Additionally, the MICs for 15-HETrE and 15-OHEPA were determined to be >0.01 , ≤ 0.05 and >0.05 , ≤ 0.075 , respectively.

Example 2: Effects of Fatty Acid Compounds in Combination with Other Compounds on the Growth of *P. Acnes*

[0119] The compounds tested singly in Example 1 were tested in combination with one another to determine the capacity of the combination to inhibit the growth of *P. acnes*. In an exemplary method, the MIC was determined for each of the combination as described in Example 1. Briefly, test combinations included DGLA with nicotinamide, benzoyl peroxide, adapalene, or metronidazole; 15-HETrE with nicotinamide, benzoyl peroxide, adapalene, or metronidazole; and 15-OHEPA with nicotinamide, benzoyl peroxide, adapalene, or metronidazole. The tables below show the growth of *P. acnes* in the presence of 0.4 or 1.0 mg/mL DGLA with varying concentrations of nicotinamide, benzoyl peroxide, adapalene, or metronidazole (Table 3); the growth of *P. acnes* in the presence of 0.01 or 0.05 mg/mL 15-HETrE with varying concentrations of nicotinamide, benzoyl peroxide, adapalene, or metronidazole (Table 5); and the growth of *P. acnes* in the presence of 0.5 or 0.1 mg/mL 15-OHEPA with varying concentrations of nicotinamide, benzoyl peroxide, adapalene, or metronidazole (Table 7).

Table 3: Combinations of Antibacterial Compositions with DGLA

Nicotinamide + 0.4mg/mL dGLA (<MIC):					Nicotinamide + 1.0mg/mL dGLA (<MIC):				
Nicotinamide [mg/mL] Index (+++, ++, +, -)				Growth Avg.	Nicotinamide [mg/mL] Index (+++, ++, +, -)				Growth Avg.
Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3		
1	+++	+++	+++	+++	1	+++	+++	+++	+++
5	+++	+++	+++	+++	5	+++	+++	+++	+++
10	+++	+++	+++	+++	10	+	++	++	++
15	+	+	+	+	15	-	-	-	-
25	-	-	-	-	25	-	-	-	-
Benzoyl Peroxide + 0.4mg/mL dGLA (<MIC):					Benzoyl Peroxide + 1.0mg/mL dGLA (<MIC):				
BPO [mg/mL] Growth Index (+++, ++, +, -)				Avg.	BPO [mg/mL] Growth Index (+++, ++, +, -)				Avg.
Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3		
0.2	+++	+++	+++	+++	0.2	++	++	+	++
0.4	+	-	-	-	0.4	-	+	-	-
0.6	-	-	-	-	0.6	-	-	-	-
0.8	-	-	-	-	0.8	-	-	-	-
1.0	-	-	-	-	1.0	-	-	-	-

Table 3 (cont.): Combinations of Antibacterial Compositions with DGLA

Adapalene + 0.4mg/mL dGLA (<MIC):					Adapalene + 1.0mg/mL dGLA (<MIC):				
Adapalene [mg/mL]				Growth Avg.	Adapalene [mg/mL]				Growth Avg.
Index (+++, ++, +, -)	Plate 1	Plate 2	Plate 3		Index (+++, ++, +, -)	Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.2	+++	+++	+++	+++
0.4	+++	+++	+++	+++	0.4	+++	+++	+++	+++
0.6	+++	+++	+++	+++	0.6	+++	+++	+++	+++
0.8	+++	+++	+++	+++	0.8	+++	+++	+++	+++
1.0	+++	+++	+++	+++	1.0	+++	+++	+++	+++

Metronidazole + 0.4mg/mL dGLA (<MIC):					Metronidazole + 1.0mg/mL dGLA (<MIC):				
Metronidazole [mg/mL]				Growth Avg.	Metronidazole [mg/mL]				Growth Avg.
Index (+++, ++, +, -)	Plate 1	Plate 2	Plate 3		Index (+++, ++, +, -)	Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.2	+++	+++	+++	+++
0.4	+++	+++	+++	+++	0.4	+++	+++	+++	+++
0.6	+++	+++	+++	+++	0.6	+++	+++	+++	+++
0.8	+++	++	++	++	0.8	+++	+++	++	+++
1.0	++	++	++	++	1.0	++	++	++	++

[0120] DGLA in combination with other compounds including nicotinamide, metranidazole or adapalene did not reduce the growth of *P. Acnes* below that of DGLA used alone. However, a spike of 0.4 mg/ml DGLA reduced the MIC obtained with benzoyl peroxide from $>0.6, \leq 0.8$ to $>0.2, \leq 0.4$. These results suggest that DGLA and benzoyl peroxide may exhibit synergy since 0.4 mg/ml DGLA has no effect on its own but when it is added to benzoyl peroxide it is able to further decrease the growth rate of *P. acnes* below that of the DGLA single compound treatment (see, Table 4).

Table 4: DGLA Combination Summary

Compound	MIC (mg/mL) as per P-11-0007 or P-11-0008 Addendum A	MIC (mg/mL) with 0.4mg/mL dGLA spike**	MIC (mg/mL) with 1.0mg/mL dGLA spike***
Metronidazole	>1	>1	>1
Nicotinamide	>10, ≤ 15	>10, ≤ 15	>10, ≤ 15
BPO	>0.6, ≤ 0.8	>0.2, ≤ 0.4	>0.2, ≤ 0.4
Erythromycin	>0.00001, ≤ 0.00005	N/App	N/App
dGLA	>0.4, $\leq 0.6^{**}$	N/App	N/App
Adapalene	>0.8	>0.6*	>0.6*
15-HETrE	>0.01, ≤ 0.05	N/App	N/App

*Precipitate observed in plates of 0.8mg/mL and higher. MIC not achieved.

**dGLA supplied by Sigma, cat# E4504

***dGLA supplied by Cayman, cat# 90230

Table 5: Combinations of Antibacterial Compositions with 15-HETrE

Nicotinamide + 0.01mg/mL 15-HETrE (<MIC):					Nicotinamide + 0.05mg/mL 15-HETrE (>MIC)				
Nicotinamide [mg/mL]	Growth Index (+++ , ++ , + , -)			Growth Avg	Nicotinamide [mg/mL]	Growth Index (+++ , ++ , + , -)			Growth Avg
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
1	+++	+++	+++	+++	1	-	-	-	-
5	+++	+++	+++	+++	5	-	-	-	-
10	++	++	++	++	10	-	-	-	-
15	-	-	-	-	15	-	-	-	-
25	-	-	-	-	25	-	-	-	-
Benzoyl Peroxide + 0.01mg/mL 15-HETrE(<MIC):					Benzoyl Peroxide + 0.05mg/mL 15-HETrE(>MIC)				
BPO [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg	BPO [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.2	-	-	-	-
0.4	+++	+++	+++	+++	0.4	-	-	-	-
0.6	++	++	++	++	0.6	-	-	-	-
0.8	+	+	+	+	0.8	-	-	-	-
1.0	-	-	-	-	1.0	-	-	-	-
Adapalene + 0.01mg/mL 15-HETrE(<MIC):					Adapalene + 0.05mg/mL 15-HETrE(>MIC)				
Adapalene [mg/mL]	Growth Index (+++ , ++ , + , -)			Growth Avg	Adapalene [mg/mL]	Growth Index (+++ , ++ , + , -)			Growth Avg
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.2	-	-	-	-
0.4	+++	+++	+++	+++	0.4	-	-	-	-
0.6	++	++	++	++	0.6	-	-	-	-
0.7	+	+	+	+	0.7	-	-	-	-
0.8	+	-	-	-	0.8	-	-	-	-
Metronidazole + 0.01mg/mL 15-HETrE (<MIC):					Metronidazole + 0.05mg/mL 15-HETrE (>MIC)				
Metronidazole [mg/mL]	Growth Index (+++ , ++ , + , -)			Growth Avg	Metronidazole [mg/mL]	Growth Index (+++ , ++ , + , -)			Growth Avg
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.2	-	-	-	-
0.4	+++	+++	+++	+++	0.4	-	-	-	-
0.6	+++	+++	+++	+++	0.6	-	-	-	-
0.8	+++	+++	+++	+++	0.8	-	-	-	-
1.0	+++	+++	+++	+++	1.0	-	-	-	-

[0121] 15-HETrE in combination with other compounds including nicotinamide, metranidazole or benzoyl peroxide did not reduce the growth of *P. Acnes* below that of 15-

HETrE used alone. However, a spike of 0.01 mg/ml HETrE to adapalene did reduce the MIC of adapalene from >0.8 to $>0.6, \leq 0.7$. These results suggest that 15-HETrE and adapalene may exhibit synergy since 0.01 mg/ml HETrE has no effect on its own but when it is added to adapalene it is able to further decrease the growth rate of *P. acnes* below that of the 15-HETrE single compound treatment (*see*, Table 6).

Table 6: 15-HETrE Combination Summary

Compound	MIC (mg/mL) as per P-11-0007 or P-11-0008 Addendum A	MIC (mg/mL) with 0.01mg/mL 15-HETrE spike	MIC (mg/mL) with 0.05mg/mL 15-HETrE spike*
Metronidazole	>1	>1	<0.2
Nicotinamide	$>10, \leq 15$	$>10, \leq 15$	<1
BPO	$>0.6, \leq 0.8$	$>0.6, \leq 0.8$	<0.2
Adapalene	>0.8	$>0.6, \leq 0.7$	<0.2
15-HETrE	$>0.01, \leq 0.05$	N/App	N/App

*0.05mg/mL 15-HETrE is an inhibitory concentration so complete inhibition was expected for all plates spiked with 0.05mg/mL.

Table 7: Combinations of Antibacterial Compositions with 15-OHEPA

Nicotinamide + 0.05mg/mL 15-OHEPA(<MIC):					Nicotinamide + 0.1mg/mL 15-OHEPA(>MIC)				
Nicotinamide [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg	Nicotinamide [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
1	+++	+++	+++	+++	1	-	-	-	-
5	+++	+++	+++	+++	5	-	-	-	-
10	+++	+++	+++	+++	10	-	-	-	-
15	-	-	-	-	15	-	-	-	-
25	-	-	-	-	25	-	-	-	-
Benzoyl Peroxide + 0.05mg/mL 15-OHEPA(<MIC):					Benzoyl Peroxide + 0.1mg/mL 15-OHEPA(>MIC)				
BPO [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg	BPO [mg/mL]	Growth Index (+++ , ++ , + , -)			Avg
	Plate 1	Plate 2	Plate 3			Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.2	-	-	-	-
0.4	++	++	++	++	0.4	-	-	-	-
0.6	+	+	+	+	0.6	-	-	-	-
0.8	-	-	-	-	0.8	-	-	-	-
1.0	-	-	-	-	1.0	-	-	-	-

Table 7 (cont.): Combinations of Antibacterial Compositions with 15-OHEPA

Adapalene + 0.05mg/mL 15-OHEPA(<MIC):					Adapalene + 0.1mg/mL 15-OHEPA(>MIC)				
Adapalene [mg/mL]				Growth Avg	Adapalene [mg/mL]				Growth Avg
Index (+++, ++, +, -)	Plate 1	Plate 2	Plate 3		Index (+++, ++, +, -)	Plate 1	Plate 2	Plate 3	
0.2	+++	+++	+++	+++	0.2	-	-	-	-
0.4	+++	+++	+++	+++	0.4	-	-	-	-
0.6	++	+++	+++	+++	0.6	-	-	-	-
0.7	++	++	++	++	0.7	-	-	-	-
0.8	++	++	+	++	0.8	-	-	-	-

Metronidazole + 0.05mg/mL 15-OHEPA (<MIC):					Metronidazole + 0.1mg/mL 15-OHEPA (>MIC):				
Metronidazole [mg/mL]				Growth	Metronidazole [mg/mL]				Growth
Index (+++, ++, +, -)	Plate 1	Plate 2	Plate 3	Avg	Index (+++, ++, +, -)	Plate 1	Plate 2	Plate 3	Avg
0.2	+++	+++	+++	+++	0.2	-	-	-	-
0.4	+++	+++	+++	+++	0.4	-	-	-	-
0.6	+++	+++	+++	+++	0.6	-	-	-	-
0.8	+++	+++	++	+++	0.8	-	-	-	-
1.0	+++	++	+++	+++	1.0	-	-	-	-

[0122] 15-OHEPA in combination with other compounds including nicotinamide, metranidazole or adapalene did not reduce the growth of *P. Acnes* below that of 15 OHEPA used alone. However, a spike of 0.05 mg/ml 15-OHEPA to benzoyl peroxide did reduce the MIC of benzoyl peroxide from >0.6, ≤0.8 to >0.4, ≤0.6. These results suggest that 15-OHEPA and benzoyl peroxide may exhibit synergy since 0.05 mg/mL has no effect on its own but when added to benzoyl peroxide it is able to further decrease the growth rate of *P. acnes* below that of the 15-OHEPA single compound treatment (see, Table 8).

Table 8: 15-OHEPA Combination Summary

Compound	MIC (mg/mL) as per P-11-0007 or P-11-0008 Addendum A	MIC (mg/mL) with 0.05mg/mL 15-OHEPA spike	MIC (mg/mL) with 0.1mg/mL 15-OHEPA spike*
Metronidazole	>1	>1	<0.2
Nicotinamide	>10, ≤15	>10, ≤15	<1
BPO	>0.6, ≤0.8	>0.4, ≤0.6	<0.2
Adapalene	>0.8	>0.8	<0.2
15-OHEPA	>0.05, ≤0.075	N/App	N/App

*0.1mg/mL 15-OHEPA is an inhibitory concentration. Complete inhibition was expected for all plates spiked with 0.1mg/mL.

Example 3: Antibacterial Effects of Various Compounds.

[0123] The compounds tested in Example 1 were tested to determine their capacity to inhibit the growth of a variety of Gram-negative bacteria, Gram-positive bacteria, fungi and yeast. In an exemplary method, Mueller Hinton agar plates were streaked with 500 μ L of a 10^5 colony-forming units/mL culture and allowed to dry for at least one minute. A sterile paper disc (6 mm diameter) was then placed in the middle of each plate using sterile forceps. Twenty microliters of a solution of a known concentration of a test compound in filter-sterilized 95% ethanol were pipetted onto each test plate. Two streaked plates served as positive inhibitory controls and contained 6 mm sterile paper discs with standard tetracycline solutions. Two additional plates served as negative inhibition controls and each contained 6 mm sterile paper discs with 20 μ L of filter-sterilized 95% ethanol. Two more plates served as positive growth controls and contained no paper disc or added antibacterial agent. The plates were incubated at 32.5 ± 2 °C. for 24 ± 4 hours, after which the corrected zone of inhibition (“CZOI”) was determined as follows:

[0124] For each plate, the length Y2 and width X2 of the test sample (paper disc) and length Y1 and width X1 of the clear zone were measured (FIG. 1). The CZOI was calculated from these values as shown by the equation below:

$$\text{CZOI} = \frac{(X1 - X2) + (Y1 - Y2)}{2}$$

[0125] Average CZOI measurements for multiple plates are shown in Tables 9 – 11 below.

Table 9: Average CZOI Values for DGLA at various concentrations.

Organism	Type	Average CZOI (mm)				
		1.4 mg/mL	1.2 mg/mL	1.0 mg/mL	0.8 mg/mL	0.6 mg/mL
<i>P. aeruginosa</i>	Gram negative bacteria	1	1	1	1	1
<i>E. coli</i>		0.25	0.5	1.5	1	1
<i>K. pneumoniae</i>		1.25	2	2.75	2	1.75
<i>S. aureus</i>	Gram positive bacteria	2	3	3	3	1.25
<i>E. faecalis</i>		1.75	2	5	3	3.25
<i>S. epidermidis</i>		1	3	6.5	3.25	4.75
<i>C. striatum</i>		2.75	4.75	2	2.75	3.75
<i>A. brasiliensis</i>	Fungus	2.25	1.75	2.75	4	1.5
<i>C. albicans</i>	Yeast	3	2	1.75	0.75	1

Table 10: Average CZOI Values for 15-HETrE at various concentrations.

Organism	Type	Average CZOI (mm)				
		0.5 mg/mL	0.1 mg/mL	0.05mg/mL	0.01mg/mL	0.005mg/mL
<i>P. aeruginosa</i>	Gram negative bacteria	1	1.5	1	1.5	1.5
<i>E. coli</i>		1	1.25	1	2	1.5
<i>K. pneumoniae</i>		1	1.5	1	2	2.5
<i>S. aureus</i>	Gram positive bacteria	1	1.75	0.75	2.5	2
<i>E. faecalis</i>		2.75	3.25	3.75	5.75	3.75
<i>S. epidermidis</i>		1.75	1	1	3	1.75
<i>C. striatum</i>		1.5	3.25	2.25	3.25	4
<i>A. brasiliensis</i>	Fungus	3	2.25	1.25	1	1.75
<i>C. albicans</i>	Yeast	1.25	1.5	1.25	1.75	2

Table 11. Average CZOI Values for 15-OHEPA at various concentrations.

Organism	Type	Average CZOI (mm)				
		0.1 mg/mL	0.075mg/mL	0.05mg/mL	0.025mg/mL	0.010mg/mL
<i>P. aeruginosa</i>	Gram negative bacteria	1.5	1.75	1.5	1	1.25
<i>E. coli</i>		1.5	1.75	1.25	1.25	2
<i>K. pneumoniae</i>		2.25	1.75	1	1.5	2.25
<i>S. aureus</i>	Gram positive bacteria	2	2.25	1.25	1	0
<i>E. faecalis</i>		1.5	1.25	2.25	1.5	2.5
<i>S. epidermidis</i>		1.25	3	2.25	2	1
<i>C. striatum</i>		1.5	2	3.5	3	3.25
<i>A. brasiliensis</i>	Fungus	2.75	3.75	2	1.75	0.25
<i>C. albicans</i>	Yeast	1	2.25	2.5	1.5	1

[0126] Based on these experiments, a summary of the most effective observed concentrations for each agent per organism is shown in Table 12, and a summary of the lowest concentration for which inhibition was observed is shown in Table 13, below.

Table 12: Summary of Most Effective Concentrations Observed.

Organism	Type	Most Effective Concentration Observed		
		DGLA	15-HETrE	15-OHEPA
<i>P. aeruginosa</i>	Gram negative bacteria	0.6 mg/mL	0.005 mg/mL	0.075 mg/mL
<i>E. coli</i>		1.0 mg/mL	0.01 mg/mL	0.001 mg/mL
<i>K. pneumoniae</i>		1.0 mg/mL	0.005 mg/mL	0.001 mg/mL
<i>S. aureus</i>	Gram positive bacteria	0.8 mg/mL	0.01 mg/mL	0.075 mg/mL
<i>E. faecalis</i>		1.0 mg/mL	0.01 mg/mL	0.001 mg/mL
<i>S. epidermidis</i>		1.0 mg/mL	0.01 mg/mL	0.075 mg/mL
<i>C. striatum</i>		1.2 mg/mL	0.05 mg/mL	0.05 mg/mL
<i>A. brasiliensis</i>	Fungus	0.8 mg/mL	0.5 mg/mL	0.075 mg/mL
<i>C. albicans</i>	Yeast	1.4 mg/mL	0.005 mg/mL	0.05 mg/mL

Table 13: Summary of Lowest Concentration With Observed Inhibition.

Organism	Type	Lowest Concentration With Observed Inhibition		
		DGLA	15-HETrE	15-OHEPA
<i>P. aeruginosa</i>	Gram negative bacteria	0.6 mg/mL	0.005 mg/mL	0.001 mg/mL
<i>E. coli</i>		0.6 mg/mL	0.005 mg/mL	0.001 mg/mL
<i>K. pneumoniae</i>		0.6 mg/mL	0.005 mg/mL	0.001 mg/mL
<i>S. aureus</i>	Gram positive bacteria	0.6 mg/mL	0.005 mg/mL	0.025 mg/mL
<i>E. faecalis</i>		0.6 mg/mL	0.005 mg/mL	0.001 mg/mL
<i>S. epidermidis</i>		0.6 mg/mL	0.005 mg/mL	0.001 mg/mL
<i>C. striatum</i>		0.6 mg/mL	0.005 mg/mL	0.001 mg/mL
<i>A. brasiliensis</i>	Fungus	0.6 mg/mL	0.005 mg/mL	0.001 mg/mL
<i>C. albicans</i>	Yeast	0.6 mg/mL	0.005 mg/mL	0.001 mg/mL

[0127] While the present disclosure has been described and illustrated herein by references to various specific materials, procedures and examples, it is understood that the disclosure is not restricted to the particular combinations of materials and procedures selected for that purpose. Numerous variations of such details can be implied as will be appreciated by those skilled in the art. It is intended that the specification and examples be considered as exemplary, only, with the true scope and spirit of the disclosure being indicated by the following claims. All references, patents, and patent applications referred to in this application are herein incorporated by reference in their entirety.

CLAIMS

The invention is claimed as follows:

1. A method of treating or preventing a microbial infection comprising administering to a subject in need thereof a pharmaceutical composition comprising 15-HETrE.
2. The method of claim 1, wherein the pharmaceutical composition is topically applied to the subject.
3. The method of claim 2, wherein the pharmaceutical composition is topically applied to a wound of the subject.
4. The method of any of the preceding claims wherein the microbial infection is a bacterial infection.
5. The method of any of the preceding claims wherein the microbial infection is a fungal infection.
6. The method of any of the preceding claims wherein the pharmaceutical composition is administered in an amount effective to treat or prevent the microbial infection.
7. The method of any of the preceding claims, wherein the pharmaceutical composition comprises about 0.1 wt.% to about 20 wt.% of 15-HETrE and one or more excipients.
8. The method of any of the preceding claims, wherein the 15-HETrE is in free acid form.
9. The method of any of the preceding claims, wherein the 15-HETrE is a pharmaceutically acceptable ester, derivative, conjugate, or salt of 15-HETrE.

10. The method of any of the preceding claims, wherein the 15-HETrE is an alkyl ester of 15-HETrE.

11. The method of any of the preceding claims, wherein the pharmaceutical composition further comprises an additional active agent selected from neomycin sulfate, polymyxin B, bacitracin zinc, ampicillin, amoxicillin, imipenem, meropenem, carbapenems, cephalexin, cephalothin, cefalozin, cefuroxime, cefotaxime, ceftazidime, fluoroquinolones, oxazolidinones, lincosamides, metronidazole, clindamycin, erythromycin, quinolone antibiotics, levofloxacin, ciprofloxacin, penicillins, glycopeptides, vancomycin, aminoglycosides, neomycin, gentamicin, tobramycin, trimethoprim/sulfamethoxazole, doxycycline, triclosan, metronidazole, monocycline and tetracycline and combinations thereof.

12. The method of any of the preceding claims, wherein the additional active agent is present in an amount that is less than a generally recognized therapeutic amount for said additional active agent.

13. The method of any of the preceding claims, wherein the 15-HETrE has been deodorized.

14. The method of any of the preceding claims, wherein the composition inhibits growth of *P. aeruginosa*, *E. coli*, *K. pneumoniae*, *S. aureus*, *E. faecalis*, *S. epidermidis*, *C. striatum*, *A. brasiliensis*, *C. albicans*, or any combination thereof.

15. A method of minimizing or preventing scarring comprising administering to a wound of a subject a pharmaceutical composition comprising 15-HETrE.

16. A pharmaceutical composition comprising 15-HETrE for use in treatment or prevention a microbial infection.

17. A pharmaceutical composition comprising 15-HETrE for minimizing or preventing scarring.

18. A pharmaceutical composition comprising 15-HETrE for use in wound healing.

19. The pharmaceutical composition of any one of claims 16 – 18 comprising about 0.1 wt.% to about 20 wt.% of 15-HETrE and one or more excipients.




Fig. 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2013/023201

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/20 (2013.01)

USPC - 514/549

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 31/20, 31/075, 31/225, 31/327 (2013.01)

USPC - 514/549, 560, 714

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

CPC - A61K 31/202, 9/0014; C07C59/40 (2013.01)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, Google Patents, PubMed Central, Google

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	US 2007/0015438 A1 (LANGE et al) 18 January 2007 (18.01.2007) entire document	1-4, 16, 18 ----- 19
Y	WO 2010/125340 A1 (KELLIHER et al) 04 November 2010 (04.11.2010) entire document	15, 17, 19
Y	WO 2007/079224 A2 (HE et al) 12 July 2007 (12.07.2007) entire document	15, 17
A	US 2003/0073930 A1 (MORRISSEY et al) 17 April 2003 (17.04.2003) entire document	1-4, 15-19

☐ Further documents are listed in the continuation of Box C. ☐

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 13 March 2013	Date of mailing of the international search report 29 MAR 2013
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Blaine R. Copenheaver PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2013/023201

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 5-14
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

摘要

本公开内容提供了用于治疗疾病和/或障碍例如皮肤感染或伤口愈合的组合物，所述组合物包含单独或与一种或多种抗生素试剂组合使用的脂肪酸或其衍生物（例如C1-C4酯），包括例如DGLA、15-OHEPA和/或15-HETrE。